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ABSTRACT
The objective of the present work is to conduct a Health Technology Assessment (HTA) on the use of the Wearable Car‑
dioverter Defibrillator (WCD) in patients at risk of Sudden Cardiac Arrest (SCA) following Myocardial Infarction (MI) or 
with an explanted Implantable Cardioverter Defibrillator (ICD).
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Abbreviations
Abbreviation Meaning
ACC/AHA/HRS American College of Cardiology/American Heart Association/Heart Rhythm Society
AE Adverse Event
AED Automated External Defibrillator
AMI Acute Miocardial Infarction
CA Cardiac Arrest
CDI Cardiac Device related Infections
CIEDI Cardiovascular Implantable Electronic Device
CPR Cardio‑pulmonary resuscitation
CABG Coronary Artery Bypass Graft
CAD Coronary Artery Disease
CEA Cost Effectiveness Analysis
COSCA Core Outcome Set for Cardiac Arrest
CUSAS Centro Universitario di Studi in Amministrazione Sanitaria
CV Cardiovascular
DRG Disease Related Group
EF Ejection Fraction
ECG Electrocardiogram
EHRA European Heart Rhythm Association
HRS Heart Rhythm Society
APHRS Asia Pacific Heart Rhythm Society
HF Heart Failure
HRQoL Health Related Quality of Life
HTA Health Technology Assessment
IADL Instrumental Activities in Daily Living
ICER Incremental Cost Effectiveness Ratio
CRT‑D Cardiac Resynchronization Therapy‑Defibrillator
ICD Implantable Cardioverter Defibrillator
ICM Ischemic cardiomyopathy
ICU Intensive Care Unit
ILCOR International Liaison Committee on Resuscitation
ISTAT Italian National Institute of Statistics
LY Life Year
LV Left Ventricular
LVEF Left Ventricular Ejection Fraction
MeSH Medical Subject Heading
MI Myocardial Infarction
NHS National Health Service
NYHA New York Heart Association
NICM Non‑ischemic cardiomyopathy
continues >




PCI Percutaneous Coronary Intervention
PTSD Post‑Traumatic Stress Disorder
QALY Quality Adjusted Life Year
RCT Randomized Clinical Trial
SAE Serious Adverse Event
SCA Sudden Cardiac Arrest
SCD Sudden Cardiac Death
SNF Skilled Nursing Facility
VA Ventricular Arrhythmia
VACAR Victorian Ambulance Cardiac Arrest Registry
VALIANT Valsartan in Acute Myocardial Infarction Trial
VAS Visual Analogic Scale
VEST Vest Prevention of Early Sudden Death Trial
VF Ventricular Fibrillation
VT Ventricular Tachycardia
WCD Wearable Cardioverter Defibrillator
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Summary
SCD is a non‑traumatic, unexpected fatal event occurring in a person without any prior 
condition that would appear fatal. By definition, a patient with SCD does not survive. When 
the patient survives, the event is termed aborted SCD or SCA. SCA is a life‑threatening condi‑
tion, recognized for being a leading cause of death worldwide. Annually, there are more than 
900,000 cases of SCA worldwide. In Italy, SCA affects over approximately 60,000 patients 
per year. The majority of these SCA events happen at home or outside of the hospital. The 
immediate cause of SCD in most instances are ventricular arrhythmias, specifically electrical 
abnormalities of the heart i.e., ventricular fibrillation (VF) or ventricular tachycardia (VT). 
However, the mechanisms are multifactorial. SCA and aborted SCD lead to serious health 
consequences for individuals and imposes a significant economic burden on the health care 
system, the patient’s family and caregivers. Furthermore, the impact on quality of life and 
activities of daily living is substantial. Costs for SCA and aborted SCD have risen over time, 
and they are expected to rise continuously due to an aging population, longer life expectan‑
cies and an increased prevalence of the underlying conditions. SCD can be prevented by a 
timely defibrillation, which is the golden standard of treatment for successfully terminating 
VF or VT. Effective treatment of SCA not only reduces mortality, but also efficiently saves 
resources otherwise used to manage the consequences of late resuscitation and intensive care 
for brain damaged patients. Accordingly, proactive and targeted investment is clearly justified 
to optimize the health status and treatment pathway in subjects at risk of SCA. An HTA on the 
use of WCD in two categories of subjects with an increased risk of SCD was performed: adult 
patients with a recent MI and adult patients with an ICD explant.
In regards to the existing published literature, the most recent reviews and meta‑analysis on 
studies involving subjects with previous MI or with previous ICD explant concluded: the WCD 
effectively bridges a limited time period, in patients with a high risk for SCA and can be a help‑
ful tool for risk stratification to better select patients for primary prevention ICD placement. The 
WCD can be considered when a transient contraindication to ICD is present, such as endocarditis 
or device related infection. The WCD is recommended in several cases, including patients with 
an ICD and a history of SCA or sustained VA in whom removal of the ICD is required, as well as 
for patients at an increased risk of SCD but who are not eligible for an ICD, with an LVEF ≤ 35% 
and within 40 days post MI. The WCD is a feasible bridge to ICD therapy and/or safe observa‑
tion for patients at high risk for SCD, especially in the acute recovery phase of cardiac diseases.
The LifeVest is the only WCD currently available and is worn outside of the body. It 
was designed to continuously monitor a patient’s heart, detects life‑threatening rapid heart 
rhythms and automatically delivers a treatment shock to restore normal heart rhythm. The 
WCD is intended for the outpatient setting, and allows patients to go home from the hospital 
with protection from SCD. The LifeVest service package includes: training and 24/7 techni‑
cal assistance and support by ZOLL Medical Corporation trained representatives; component 
replacement within 24 hours; cleaning and testing procedures of the device with recondition‑
ing or repair completed when required; inclusion in the LifeVest Network. This is an online 
patient management system, that allows clinicians to monitor patient data downloaded from 
the device and it gives health care professionals access to the most current information about 
their patient during their recovery after a cardiac event.
The experience on the use of WCD shows promising results. In the most recent random‑
ized trial, the WCD was highly effective at restoration of sinus rhythm in patients with a VT/
VF and significantly decreased overall mortality, although no statistically significant SCD 
mortality benefit was reported, most likely due to insufficient power of the study. However, 
as experience with this technology increases, it is expected that clinical benefits for WCD use 
will be better recognized.
In post‑MI patients, the base‑case analysis conducted from the Italian NHS point of view, 
reported an ICER of € 47,709 per QALY gained comparing WCD vs medical therapy, which 
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is significantly lower than the referenced cost‑effectiveness threshold of € 60,000 per QALY 
gained used in Italy. This analysis was based on the overall mortality at 90 days data estimated 
in the VEST trial by the Intention to Treat Analysis (ITT) which reflects the low WCD adher‑
ence of the patients involved in the trial: 3.1% overall mortality at 90 days in the WCD group 
and 4.9% in the medical therapy group. Using ITT mortality data is a conservative approach, 
considering the better efficacy reported by the VEST Trial in the “As Treated” analysis (0.50 
per 100 person‑months of patients wearing the WCD and 1.91 per 100 person‑months of 
patients not wearing the WCD). It seems that the adherence seen in published observational 
studies reflects the assumptions in the “As Treated” analysis. Although an economic model 
calculating the cost‑effectiveness of WCD was not conducted on the “As Treated” cohorts, 
it is clear that cost calculations conducted with this data would be lower than those reported 
for the ITT economic model. Further, a cost‑minimization analysis was conducted in patients 
requiring ICD explant due to an associated infection, since this option was assumed to be 
equivalent compared with the standard therapy (3 weeks hospitalization in a low intensity 
hospital). In this analysis, made from the Italian NHS point of view, the WCD provides a cost 
saving of € 1,782 per patient. The results of the two models were confirmed with univariate 
and probabilistic sensitivity analyses.
In conclusion, the use of WCD according to guidelines can therefore contribute not only 
to an improvement in patient care in clinical practice, but also to a more effective utilization 
of resources in the Italian NHS. In addition, further research on risk factors for SCA and SCD 
should be conducted to continue to improve the identification of the target population. All 
evidence provided in this HTA was considered reliable by Italian clinical and HTA experts. 
Accordingly, the results can be considered applicable within the Italian NHS.
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Objective and Methods
OBJECTIVE
The objective of the present work is to conduct a Health Technology Assessment (HTA) 
on the use of the Wearable Cardioverter Defibrillator (WCD) in patients at risk of Sudden 
Cardiac Arrest (SCA) following Myocardial Infarction (MI) or with an explanted Implantable 
Cardioverter Defibrillator (ICD).
METHODS
The present work was conducted using previous HTA reports as a guide [1‑4]. In particu‑
lar, we described the target health condition from a clinical and epidemiological perspective, 
its economic burden and consequences on patients’ health and on their families’ wellbeing. 
We also described the WCD technology, and its implications in terms of effectiveness, safety, 
compliance, and in the health economic implications from a national payer perspective.
The present work was conducted using mainly an extensive literature research, but also 
using the advises of clinical experts and the application of a decision analytical model to con‑
duct economic evaluations.
Research of data from literature
We performed an extensive literature search, adopting the following approach. First, elec‑
tronic databases (Medline using PubMed and Web of Science) were consulted on 1st March 
2018. We conducted the research using index/MeSH (Medical Subject Heading) and strings 
of keyword terms, according to the field of research: clinical description of the target condi‑
tions; epidemiological description of the target conditions; treatment with focus on WCD 
use; treatment with focus on other options (e.g., ICD); economic implications (i.e., burden 
of disease, economic evaluations); patients reported outcomes and Health Related Quality of 
Life (HRQoL). The research strings included the following terms:
1. (“Sudden Cardiac Death” OR “Sudden Cardiac Attack” OR “Sudden Cardiac Arrest”) 
AND (“prevalence” OR “incidence” OR “mortality” OR “survival” OR “life expectancy” 
OR “risk” OR “death”) for the epidemiological domain;
2. (“Sudden Cardiac Death” OR “Sudden Cardiac Attack” OR “Sudden Cardiac Arrest”) 
AND (“symptoms” OR “cause” OR “diagnosis” OR “prognosis” OR “severity” OR “risk” 
OR “treatment” OR “therapy” OR “death”) for clinical domain;
3. (“Sudden Cardiac Death” OR “Sudden Cardiac Attack” OR “Sudden Cardiac Arrest”) 
AND (“treatment” OR “therapy” OR “implantable cardioverter defibrillator “OR “ICD” 
AND “efficacy” OR “effectiveness” OR “benefit” OR “outcome” OR “resuscitation” OR 
“risk” OR “safety” OR “adverse event” OR “side effect” OR “LifeVest” OR “wearable 
cardioverter defibrillator” OR “WCD”) for treatment domain (including LifeVest);
4. (“Sudden Cardiac Death” OR “Sudden Cardiac Attack” OR “Sudden Cardiac Arrest”) 
AND (“quality of life” OR “health related quality of life” OR “patient perspective” OR 
“patient reported outcomes” OR “utility” OR “wellbeing”) for quality of life and psycho‑
social domain;
5. (“Sudden Cardiac Death” OR “Sudden Cardiac Attack” OR “Sudden Cardiac Arrest”) 
AND (“cost” OR “economic” OR “burden” OR “cost of illness” OR “cost of treatment” 
OR “cost consequences” OR “cost‑effectiveness” OR “cost benefit” OR “cost utility”) for 
economic domains.
Eligibility criteria included the target disease area, the age of the subjects (adults), the 
language (English or Italian), years of publication (2008 and later) and type of publications: 
original research from clinical trials, observational retrospective or prospective studies, lit‑
erature reviews, guidelines and practice guidelines published on clinical and epidemiological 
evidence. In order to find the most updated documents, further literature research focusing on 
10 Farmeconomia. Health economics and therapeutic pathways 2021; 22(Suppl 1)
Objective and Methods 
specific topics (e.g., new papers on WCD and on HRQoL in patients experiencing SCA (Sud‑
den Cardiac Arrest) were found published in late March and in July 2018) was conducted in 
April and in July 2018. Furthermore, the Vest Prevention of Early Sudden Death Trial (VEST) 
[5], published in September 2018, was included as well. All identified titles found were ana‑
lyzed and duplicates were removed.
After a first screening process based on the title and abstract of article retrieved, a full‐text 
screening was conducted. From the included publications, we searched the full‑texts and then 
screened their references lists to identify other possible relevant ones, following the same 
process above of publication selections from the titles and abstracts. Finally, we read the full 
texts for a final selection of the eligible publications. Two of the authors (L.S.D. and L.S.) 
independently evaluated eligibility of all the studies retrieved from the electronic literature 
search. Two other reviewers (P.A.C. and L.G.M.) were also involved to reach consensus in 
case of disagreement. Exclusion criteria included all documents not reporting any informa‑
tion on our target populations (i.e., on post‑MI patients and on ICD explanted). Regarding the 
publications reporting results on safety, effectiveness and compliance of WCD in the target 
populations, we also checked if overlapping of participants were present in two or more stud‑
ies. Studies characteristics and data reported were systematically extracted by two authors 
(L.S.D. and L.S.) according with and reported in pre‐defined structured table. A third author 
(P.A.C.) subsequently validated data extraction independently. Any disagreement on data ex‑
traction was resolved by discussion. The evidence extracted by the literature were used to 
draft this HTA.
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Results
The information found in the selected literature proved useful to describe the several as‑
pects of the phenomenon under study, is reported below and quoted. The list of publications 
retrieved by the literature review on WCD in patients with MI and/or with ICD explant is 
reported in Table I.
n. Reference Subjects Type of study Study design
1 Agarwal et al. 2018 [6] Mixed indication Review Not Applicable
2 Ellenbogen et al. 2018 [7] Mixed indication Original Research Retrospective
3 Leyton‑Mange et al. 2018 [8] Mixed indication Original Research Retrospective
4 Nguyen et al. 2018 [9] Mixed indication Meta‑Analysis Not Applicable
5 Niwano et al. 2018 [10] Mixed indication Review Not Applicable
6 Olgin et al. 2018 [5] POST AMI Original Research Clinical trial (VEST) Randomized
7 Röger et al. 2018 [11] Mixed indication Original Research Prospective
8 Viani et al. 2018 [12] Mixed indication Review Not Applicable
9 Weinstock et al. 2018 [13] Mixed indication Review Not Applicable
10 Al Khatib et al. 2017 [14] Mixed indication Guidelines Not Applicable
11 Barraud et al. 2017 [15] POST AMI Original Research Prospective
12 Barraud et al. 2017 [16] Mixed indication Review Not Applicable
13 Barsheshet et al. 2017 [17] Mixed indication Original Research Clinical trial (SWIFT) Prospective
14 Beiert et al. 2017 [18] Mixed indication Original Research Retrospective
15 Cappato et al. 2017 [19] Mixed indication Review Not Applicable
16 Castro et al. 2017 [20] EXPLANTED Original Research Retrospective
17 Ellenbogen et al. 2017 [21] EXPLANTED Original Research Retrospective
18 Erath et al. 2017 [22] Mixed indication Original Research Prospective
19 Ettinger et al. 2017 [23] Mixed indication HTA Not Applicable
20 Francis 2017 [24] Mixed indication Editorial Not Applicable
21 Naniwadekar et al. 2017 [25] Mixed indication Original Research Retrospective
22 Nichol et al. 2017 [26] Mixed indication Review Not Applicable
23 Quast et al. 2017 [27] Mixed indication Original Research Retrospective
24 Reek et al. 2017 [28] Mixed indication Review Not Applicable
25 Reek et al. 2017 [29] Mixed indication Review Not Applicable
26 Sasaki et al. 2017 [30] Mixed indication Original Research Prospective
27 Tofield 2017 [31] Mixed indication Letter Not Applicable
28 Bhaskaran et al. 2016 [32] Mixed indication Original Research Retrospective
29 Duncker et al. 2016 [33] Mixed indication Review Not Applicable
30 Piccini et al. 2016 [34] Mixed indication Recommendation Not Applicable
31 Ponikowski et al. 2016 [35] Mixed indication Guideline Not Applicable
32 Wäßnig et al. 2016 [36] Mixed indication Original Research Retrospective
33 Healy et al. 2015 [37] EXPLANTED Original Research (Economic evaluation) CEA based on 
decision model
34 Kondo et al. 2015 [38] POST AMI Original Research Retrospective
continues >
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n. Reference Subjects Type of study Study design
35 Kutyifa et al. 2015 [39] Mixed population Original Research WEARIT‑II Registry Prospective
36 Priori et al. 2015 [40] Mixed indication Guideline Not Applicable
37 Sanders et al. 2015 [41] POST AMI Original Research (Economic evaluation) CEA based on 
decision model
38 Sasaki et al. 2014 [42] Mixed indication Original Research Prospective
39 Chung 2014 [43] Mixed indication Review Retrospective
40 Francis et al. 2014 [44] Mixed indication Review Not Applicable
41 Kusumoto et al. 2014 [45] Mixed indication Expert Consensus Not Applicable
42 Pedersen et al. 2014 [46] Mixed indication Expert Consensus Not Applicable
43 Tanawuttiwat et al. 2014 [47] EXPLANTED Original Research Retrospective
44 Adler et al. 2013 [48] Mixed indication Review Not Applicable
45 Epstein et al. 2013 [49] POST AMI Original Research Retrospective
46 Klein et al. 2013 [50] Mixed indication Review + reporting results from 
a previous original research
Retrospective 
as regard as the 
original research
47 Zishiri et al. 2013 [51] Mixed indication Original Research Retrospective
48 Kao et al. 2012 [52] Mixed indication Original Research Retrospective
49 Chung et al. 2010 [53] Mixed indication Original Research Retrospective
50 Dillon et al. 2010 [54] Mixed indication Original research Retrospective
51 Verdino et al. 2010 [55] Mixed indication Review Not Applicable
52 Wilkoff et al. 2009 [56] EXPLANTED Expert consensus Not Applicable
53 Feldman et al. 2004 [57] Mixed indication Original Research Results of WEARIT/
BIROAD study
Prospective
Table I. List of publications on WCD where patients with MI and/or with ICD explant were involved
> continued
EPIDEMIOLOGICAL DESCRIPTION OF TARGET 
CONDITION AND CLINICAL IMPACT
Sudden Cardiac Death (SCD) can be defined as a non‑traumatic, unexpected fatal event 
occurring within 1 hour of the onset of symptoms in a person without any prior condition 
that would appear fatal [40,58,59]. SCD may be preceded by symptoms such as chest pain, 
dyspnea, palpitations, pre‑syncope and syncope, although many individuals have no symp‑
toms before the event. By definition, a patient with SCD does not survive. When the patient 
survives, the event is termed aborted SCD or SCA.
Sudden Cardiac Arrest
SCA is a life‑threatening condition, recognized for being a leading cause of death world‑
wide. Annually, there are approximately 375,000‑700,000 SCA cases in Europe [60], and 
around 360,000‑380,000 cases in the US [61,62]. Mozaffarian et al. [63] stated that according 
to estimations, in the US, 326,000 persons are affected by SCAs outside of the hospital annu‑
ally, and a large part of these SCAs happen at home.
Ellenbogen et al. [7] stated that according to the American Heart Association 2013 Heart 
Disease and Stroke Statistics, 209,000 in‑hospital and 359,400 out‑of‑hospital cardiac arrests 
occur annually.
In their literature review, Haydon and colleagues state that internationally the survival 
rate for Cardiac Arrest (CA) is less than 14% [64]. In particular, Ellenbogen and colleagues 
[7] specified that despite advances in care management, the outcome of patients experienc‑
ing in‑hospital SCA remains poor, with survival to hospital discharge rates varying from 6% 
to 18%. In addition, many SCAs occur when the patient is out‑of‑hospital, asleep or alone. 
According to the results by Perkins and colleagues [65], among patients with out‑of‑hos‑
pital CA, only 2.4% survived at 30 days. Furthermore, survivors of out‑of‑hospital CA 
may sustain brain damage due to inadequate cerebral perfusion during cardiac arrest. After 
out‑of‑hospital CA, constant care or assistance with activities of daily living and nursing 
home care may be needed [66]. In Italy, within the “Piacenza Progetto Vita” [67], the first 
European system of out‑of‑hospital early defibrillation by lay volunteers, established in the 
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Area of Piacenza (a city in the Emilia Romagna region) to prevent SCD, 39 semi‑automatic 
external defibrillators were deployed in the city and in the surrounding. During the first 22 
months from the beginning of the project, 354 SCA occurred: 86% in the home, 11% in 
public streets, less than 1% in an athletic center, 1% at work and 1% in other places. The 
mean age of the victims was 72 (± 12 years); 61% were male. The volunteers, answering to 
the emergency call number within an average of 4.8 minutes from the call, treated more than 
40% of CAs and the survival percentage increased from 4.3% to 15.5% [67]. Although the 
current evidence supports the association between bystander automatic external defibrillator 
(AED) use and improved clinical outcomes [68], the use of AEDs has been identified for not 
being optimal to manage out‑of‑hospital CA, since most patients at risk do not spend a suf‑
ficient portion of each day in public locations [69]. The wearable cardioverter defibrillator 
aims to overcome these issues.
Sudden Cardiac Death
The immediate cause of SCD in most instances is Ventricular Arrhythmia (VA) secondary 
to structural heart disease or primary electrical abnormalities of the heart i.e., either Ven‑
tricular Fibrillation (VF) or Ventricular Tachycardia (VT). However, the mechanisms are 
multifactorial and include scar formation, fibrosis, ventricular dilatation, re‑entry, abnormal 
automaticity [70‑74].
Table II, adapted from Kuriachan and colleagues [71], shows the major causes of SCD. 
SCD has a multitude of potential etiologies but is most commonly associated with ischemic 
heart disease, while Non‑Ischemic Cardiomyopathy (NICM) and other structural abnor‑
malities may also be causative. Patients without structural disease have a primary electrical 
abnormality like long‑QT syndrome or Brugada syndrome. Severe left ventricular systolic 
dysfunction is the main marker for sudden death in patients with ischemic or NICM [71]. 
Genetic factors can play a role in SCD in the pathophysiological pathway. Mutations and 
polymorphisms can influence the risk of SCD in both Coronary Artery Disease (CAD) and 
non‑CAD etiologies, while other risk factors include smoking, hypertension, dyslipidemia, 
obesity, diabetes and lifestyle [75].
SCD occurs in 184,000‑462,000 individuals in the US annually, with an incidence of 60 
per 100,000 individuals per year, accounting for 5.6% of all deaths in the US [70,71,76]. 
Kuriachan and colleagues [71], using death certificate data, report that SCD accounts for up to 
15% of all deaths in Western nations. According to Capucci et al. [67] about 45,000 SCDs oc‑
cur every year in Italy, and incidence of SCD in Italy was estimated to be from 55,000‑60,000 
persons per year [77].
Subjects with the highest risk of SCA and SCD are those with known heart disease, al‑
though the majority of SCDs occur in low‑risk populations [78]. The incidence of SCD in‑
creases 2‑ to 4‑fold, in the presence of coronary disease and 6‑ to 10‑fold in the presence of 
structural heart disease [74]. The estimated incidence of SCD is about 15‑20% per year in 
patients with heart failure and/or with arrhythmia markers, compared with about 1‑2% per 
year occurring in the general population, who generally have an unknown pre‑existing heart 
disease [79]. In individuals with known CAD or a prior MI, this population accounts for 
38‑50% of all cardiovascular deaths [79]. However, a significant proportion of SCD happens 
also in patients with NICM [72,80].
SCD incidence increases with age and is generally more frequent in men. The incidence of 
SCD in younger populations (<30 years) is 100‑fold lower than that in older individuals [71]. 
Data from MONICA study [81], conducted in Italy between 80s and early 90s referred a wide 
range of incidence of SCD, according to age. The incidence of SCD was 0.1/1,000 in men at 
35‑44 years of age, 0.37/1,000 in men at 45‑64 years of age, 0.88/1,000 in men at 55‑64 years 
of age and 2.86/1,000 in men at 65‑74 years of age. Women are relatively protected from SCD 
until the menopausal years when the incidence increases to approach that of men. The lifetime 
risk of SCD for women is at least half that of men. Results from a work recently published 
[82], conducted using individual participant data from the Framingham Heart Study, reported 
a lifetime risk estimate for SCD of 10.1‑11.2% in men aged 45, 55, and 65 years, and of 
2.4‑3.4% in women at the same age.
Stecker and colleagues [76] found that in men, SCD incidence exceeds other causes of 
death including cancers (lung, prostate, and colorectal), accidents, chronic respiratory dis‑
eases, diabetes, and cerebrovascular disease. In women, SCD incidence is similar or higher 
to that of different types of cancer, cerebrovascular disease, Alzheimer disease, and accidents.
Wellens et al. [83] classified 4 different groups of individuals at risk of SCD: patients with 
a history of heart disease and severe cardiac dysfunction (Left Ventricular Ejection Fraction – 
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LVEF <40%), accounting for 13% of SCD, 
and patients with a history of heart disease 
with no or mild cardiac dysfunction (LVEF 
>40%), accounting for 40% of SCD. There 
are also patients who are diagnosed with 
a genetically based cause for a life‑threat‑
ening cardiac arrhythmia, accounting for 
2% of SCD. Finally, there is a large subset 
without a prior diagnosis of heart disease, 
accounting for 45% of all SCD: in these 
populations, risk stratification is particularly 
challenging.
An inverse relationship between the inci‑
dence of SCD and absolute numbers of 
events in the various epidemiologic or clini‑
cal categories was reported [59]. When SCD 
is analyzed in terms of the absolute number 
of annual events within subpopulations, as 
shown in Figure 1, it is possible to see that 
the highest risk clinical subgroups, i.e., pa‑
tients with reduced LVEF, a history of heart 
failure, and survivors of out‑of‑hospital car‑
diac arrests, do not generate most SCD 
events. Instead, subgroups with the highest 
case fatality rates have the lowest population 
attributable risk. In contrast, the larger popu‑
lation subgroups, with much lower relative 
fatality rates, generate the largest absolute 
numbers of SCD events. Myerburg et al. 
[84] affirmed that the importance of recog‑
nizing this principle relates to the magnitude 
of population that can benefit from preventative interventions. For example, the very high‑risk 
patient categories studied in the clinical trials of implantable defibrillators represent only a 
very small part of the universe of SCD risk, and the reported benefits apply only to those small 
subgroups. This highlights the importance of finding specific risk markers for more general 
segments of the population from which the potential for greater public health impact can 
emerge.
Major causes Causes description
Ischemic heart 
disease
 • CAD with MI
 • CAE





 • Hypertrophic cardiomyopathy
 • Dilated cardiomyopathy
 • VHD
 • CHD
 • Arrhythmogenic right ventricular cardiomyopathy
 • Myocarditis
 • Cardiac tamponade
 • Acute myocardial rupture
 • Aortic dissection
No structural 
heart disease
 • Idiopathic ventricular fibrillation or J‑wave syndrome
 • Brugada syndrome
 • Long‑QT syndrome with torsades de pointes
 • Pre‑excitation syndrome
 • High grade atrioventricular block with torsades de pointes
 • Familial SCD
 • Commotio cordis
Non‑cardiac 
disease
 • Pulmonary embolism
 • Intracranial hemorrhage
 • Drowning
 • Pickwickian syndrome
 • Drug overdose or toxicity
 • Central airway obstruction
 • Sudden infant death syndrome
Table II. Major causes of SCD. Adapted from [71]
CAD = Coronary Artery Disease; MI = Myocardial Infarction; CAE = Coronary 
Artery Embolism; CAS = Coronary Artery Spasm; VHD = Valvular Heart Disease; 
CHD = Congenital Heart Disease; SCD = Sudden Cardiac Death
Figure 1. Incidence of SCD and total population burden: relationship between population subsets. Modified from [84]
AVID = Antiarrhythmics vs Implantable Defibrillator study, CASH = Cardiac Arrest Study Hamburg; CIDS = Canadian Implantable Defibrillator Study; 
EF = Ejection Fraction; MADIT = Multicenter Automatic Defibrillator Implantation Trial; MI = Myocardial Infarction; MUSTT = Multicenter UnSustained 
Tachycardia Trial; SCD‑HeFT = The Sudden Cardiac Death in Heart Failure Trial, VT/VF = Ventricular Tachycardia–Ventricular Fibrillation
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Patients with MI (at risk of SCA)
Subjects experiencing an Acute Myocardial Infarction (AMI) remain at high risk of SCD. 
Several studies have quantified the risk of SCD after MI, estimating an overall incidence rang‑
ing between 2% and 4% per year [85‑88].
The Valsartan in Acute Myocardial Infarction Trial (VALIANT) [86,87], a Randomized 
Controlled Trial (RCT) involving 14,609 patients with a first or subsequent AMI complicated 
by Heart Failure (HF) and LVEF ≤40% assessed the risk and time course of sudden death 
in high‑risk patients, after MI. In the trial, 7% of the participants had an event a median of 
180 days after MI: 903 died suddenly and 164 were resuscitated after SCA. Of these events, 
19% occurred within the first 30 days post‑MI with 74% of the patients that were resuscitated 
still alive one year later. The risk of an event was 10‑fold higher in the first 30 days at a rate 
of 1.4% per month, decreasing exponentially over the first 6 months to reach a steady rate 
of 0.14% per month, at 2 years. Patients with an LVEF ≤30% demonstrated the highest risk 
in this early period. This significant higher risk of SCD within the first month after MI was 
confirmed in several other studies [89‑93]. However, the risk of SCD in patients after MI 
estimated in clinical trials can be different from the one present in the community. Further‑
more, since advances in therapies for MI have increased the numbers of survivors living with 
chronic CAD and impaired left ventricular function [94‑98], more patients nowadays live at 
increased risk of fatal and non‑fatal events [86,87,99]. A large, population‑based study was 
conducted in the Olmsted County in Minnesota to evaluate the risk of SCD post‑MI and the 
impact of recurrent ischemia and HF on SCD [89]. In this study observing 2,997 subjects for 
a median follow‑up of 4.7 between the years 1979 and 2005, 1,160 deaths occurred, 24% 
of these being SCD. The 30‑day cumulative incidence of SCD was 1.2%. The risk of SCD 
declined over time after the first 30 days. Recurrent ischemia was not associated with SCD, 
since the incremental risk, expressed as hazard ratio, corresponded to 1.26, with a 95% CI= 
0.96‑1.65, while HF markedly increased the risk of SCD, corresponding to a hazard ratio of 
4.20, with a 95% CI=2.9‑5.8. The authors underline the importance of continued surveillance 
of patients who experienced an MI and the dynamic nature of risk stratification.
Patients with ICD explant
Prevention of SCA after ICD removal is a challenging issue. The most common indica‑
tions for lead replacement are infection, venous occlusion, advisory or recall for possible lead 
malfunction, or mechanical lead failure. Lead management involves the assessment of risks 
and benefits of whether or not to remove the lead based on the individual clinical condition of 
the patient as well as lead characteristics [100‑102].
Infection of an ICD or other type of cardiac implantable electronic device (e.g., pacemak‑
er) is associated with significant morbidity, mortality and costs, which increase correspond‑
ingly to higher implantation rates [47,101,103‑107]. This phenomenon has consequently in‑
creased the percentage of infections by 96‑210% estimated between 1993 and 2008 [47,101]. 
Complete system removal together with parenteral antibiotic therapy are recommended for 
patients who do not tolerate the procedure [102]. Despite device removal with antibiotic 
therapy, mortality remains high, ranging from 8.0% to 26.9%, while antibiotic therapy alone 
without device removal carries a higher mortality corresponding to 31.0–66.0% [47].
Sridhar and colleagues [103] examined recent national trends in the incidence of Cardiac 
Device related Infections (CDI), and lead extractions in hospitalized patients and associated 
mortality. Using the data of a Nationwide Inpatient Sample database in the US, they identified 
for the years 2003 and 2011 patients diagnosed with a CDI as determined by discharge ICD‑9 
diagnostic codes. They found an increase in the number of hospitalizations due to CDI from 
5,308 in the year 2003 to 9,948 in 2011. Males (68%), Caucasians (77%) and age group 65–84 
years (56.4%) accounted for majority of CDI. The mortality associated with CDI was 4.5%, 
and was significantly worse in higher age groups: 2.5% in 18‑44 years compared to 5.3% in 
>85 years. Mean hospitalization charges increased from $ 91,348 in 2003 to $ 173,211 in 
2011. Among all lead extraction procedures, the percentage of patients undergoing lead ex‑
traction secondary to CDI also increased from 2003 (59.1%) to 2011 (76.7%).
The management of patients after ICD removal waiting for re‑implantation is challenging 
for more reasons, since, implanting the device too early may result in re‑infection, the patients 
remain at risk of SCA, and continuous inpatient monitoring is expensive and not beneficial for 
the patient’s health and quality of life [37]. Depending on the patient’s risk, the clinician could 
decide to prolong patient’s hospitalization to prevent arrhythmic death, or to consider a device 
re‑implantation before achieving infectious control.
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Consequences on health and quality of life of subjects surviving CA
As the brain is highly dependent on a constant blood flow, survivors may suffer from 
long‑term cognitive impairment, which could involve one third or up to 50% of the CA survi‑
vors [108‑110]. Several publications have been found from our literature research conducted 
in March and updated in June. We summarize below the results and discussions of those that 
we found of highest interest on the target topic.
In particular, decrease in social participation and psychiatric condition in survivors to 
CA have been reported in several publications in the last years. To report the findings of the 
most recent ones, for instance, Naber and Bullinger [111] listed as cognitive impairment 
symptoms in their short report: memory impairment, attention impairment, executive func‑
tion, impairment of visual‑spatial abilities and verbal fluency, specifying that there is no con‑
sensus on whether cognitive deficits recover over time. Naber and Bullinger underlined that 
while in the past the interest in the long‑term outcomes of patients surviving out‑of‑hospital 
CA focused on neurological symptoms, in the last decade, psychiatric symptoms, mental 
health or more broadly, HRQoL have become areas of scientific interest. Few years ago, 
patient‑reported outcomes and HRQoL were included as supplemental outcomes in the stan‑
dardized Utstein Resuscitation Registry Templates for out‑of‑hospital CA [112]. More re‑
cently, a consensus article has been published [113] on the Core Outcome Set for Cardiac 
Arrest (COSCA) initiative, in collaboration with the International Liaison Committee on 
Resuscitation (ILCOR): after a systematic literature review, a Delphi panel was adopted on 
168 participants who were clinicians, patients and their relatives meeting for two days. The 
consensus reached recommends that a core outcome set for reporting on effectiveness studies 
of cardiac arrest in adults should include survival, neurological function, and HRQoL. This 
should be reported as survival status and modified Rankin scale score at hospital discharge, 
at 30 days, or both, while HRQoL should be measured with ≥1 tools from health utilities in‑
dex version 3, Short‑Form 36‑Item Health Survey, and EQ‑5D‑5L at 90 days and at periodic 
intervals up to 1 year after CA.
As regards other studies more recently published, Viktorisson and colleagues [114] no‑
ticed that although psychological problems following CA have been increasingly highlighted 
in recent years, there is still paucity of optimal services to provide cognitive, psychological 
and psychosocial support and rehabilitation. Their cross‑sectional study aimed to assess the 
presence of anxiety, depression and Post Traumatic Stress Disorder (PTSD) and to compare 
the health state of patients surviving to OHCA and with a good neurological condition with 
a reference population in Sweden. Survivors were identified through the Swedish Cardio‑
pulmonary Resuscitation Registry, and postal questionnaires were sent out 3 months after 
the out‑of‑hospital CA. Main findings were that reduced wellbeing was experienced by half 
of the patients, above all among older patients and among women and in comparison, with a 
reference population in Sweden.
Tiainen and colleagues [115] conducted recently a prospective observational study to 
evaluate the functional status and HRQoL of one‑year survivors of a cohort of unconscious 
patients that after out‑of‑hospital CA were admitted to Finnish intensive care units during 
one year. They assessed the proportion of survivors living at home one year after the event, 
their functional outcome regarding independency in Instrumental Activities in Daily Living 
(IADL) functions, activities outside home, return to previous work, car driving, and their 
self‑rated HRQoL. Nine out of ten one‑year survivors of the participants experienced good 
neurological and functional outcome, living at home and being independent in basic daily 
functions. HRQoL was similar as in age‑ and sex‑adjusted Finnish population. Less than 10% 
of the one‑year survivors lived in long‑term facilities, and only 3% of the patients who lived at 
home before the arrest needed long‑term facility care one year later. This need was not based 
solely on the hypoxic‑ischemic brain injury.
According to Andrew and colleagues [116], understanding the prognosis of elderly pa‑
tients with out‑of‑hospital CA is important to inform decision‑making in resuscitation and 
advanced care planning. However, short‑term outcomes such as survival to hospital discharge 
cannot be considered to understand the post‑arrest HRQoL of the patients. They conducted a 
retrospective analysis of data gathered from the Victorian Ambulance Cardiac Arrest Registry 
(VICAR) on 20,103 out‑of‑hospital CA survivors to hospital discharge aged ≥65 years, to 
describe the 12‑month functional recovery and HRQoL of these subjects. During the study 
period, 44.9% of the participants received a resuscitation attempt, 9.7% of the patients sur‑
vived to hospital discharge and 777 were alive 12 months post‑arrest. Of these, 651 (83.8%) 
participated in 12‑month follow‑up. Most (60.6%) resided at home without additional care 
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and 66.6% reported a good functional recovery, although these percentages decreased with 
increasing age. Furthermore, the authors of the research found that each 10‑year increase in 
age corresponds with a 40.8% reduction in the odds of good functional recovery, and a 65.8% 
reduction in the odds of living independently. Physical HRQoL decreased with increasing 
age, but mental HRQoL increased (not statistically significant) with increasing age and was 
significantly better than the age‑ and sex‑matched Australian population. Of the 2575 OHCAs 
in an aged care facility, 2.2% survived to hospital discharge; however, no patient reported a 
good 12‑month functional recovery.
A sub‑study of the VALIANT study [117] involved 2556 patients who completed the 
EQ‑5D at baseline and after 6, 12, 20, and 24 months. Over a 2‑year period, 597 patients 
experienced a nonfatal CV event, with baseline EQ‑5D scores on average lower than patients 
without a subsequent nonfatal CV event (Visual Analogic Scale – VAS = 61.0 ± 19 vs 68.2 ± 
18; p < 0.001 and US‑based utility score = 0.76 ± 0.22 vs 0.83 ± 0.17; p < 0.001). Accordingly, 
patients surviving to MI who experienced a subsequent nonfatal CV event had a significant 
worsening of their HRQoL in addition to a worse overall baseline HRQoL compared with 
patients with MI who did not experience another CV event over 2 years.
Van’t Wout et al. [118] determined the level of daily functioning and quality of life in 
caregivers of cardiac arrest survivors two years after the cardiac arrest. Furthermore, they 
studied the long‑term impact of witnessing the event of a CA. A longitudinal cohort study 
including caregivers of cardiac arrest survivors completed a questionnaire at home on daily 
activities, emotional functioning, fatigue, caregiver strain, impact of event, and quality of 
life. In total 57 caregivers participated. Two years after the cardiac arrest, their quality of life 
was similar to those of the general population, although almost 30% still scored high level of 
trauma‑related stress. However, the study showed that two years after the CA, caregivers that 
attended the event of CA, experienced significantly more trauma related stress than caregivers 
who did not experienced the event. The authors of the research recommend future research to 
focus on screening for stress related to attending a CA of a close relative and the effectiveness 
of support programs for caregivers that attended a cardiac arrest of a close relative. Another 
study [119] has shown that in terms of wellbeing, caregivers experience the most problems 
on the emotional level at one year after the cardiac arrest. Generally, they improve within 
12 months from the event, apart from those with emotional problems or perceived cognitive 
problems at 12 months, who are at risk for developing a higher care burden. However, also 
less recent studies provide interesting results. For instance, a study conducted in the Nether‑
lands and published in 2009 [120] showed that patients had low participation level in soci‑
ety (74%), severe fatigue (more than 50%), anxiety and/or depression (38%) and decreased 
HRQoL (24%) and that clinically relevant PTSD symptoms were present in 50% of the family 
caregivers, compared with 21% of patients themselves. They concluded that after surviving 
an out‑of‑hospital CA, both patients and partners could experience important impairments in 
their lives, similar to those seen in patients with other kinds of brain damage. In a study pub‑
lished in 2014 [121], PTSD was found in 40% of relatives of patients with out‑of‑hospital CA.
Despite the different aims and methods and healthcare contexts where the several stud‑
ies have been conducted across the years, bearing to different and generally not comparable 
results, it is possible to conclude that relevant consequences on health, both clinical and per‑
ceived ones, of patients and their families who have experienced CA, can be substantial; 
accordingly, attention and correct investment is deserved to optimize the health states in in‑
volved subjects.
ECONOMIC IMPLICATIONS OF SCA AND SCD
SCA and SCD impose a significant economic burden on patients, on their families and on 
healthcare systems. Costs for SCA and SCD have risen over time, and are expected to rise 
due to an aging population and increase of prevalence of these conditions. However, a com‑
prehensive estimate of economic consequences attributable to SCA and SCD does not exist.
The most recent study found on this topic, published in 2018 [122] was conducted in Tai‑
wan. Interestingly, the authors aimed to estimate the 1‑year survival rate and related health‑
care costs after CA in a population randomly sampled from the National Health Insurance 
Research Database. They estimated a mean cost per hospital discharge after cardiac arrest 
less than $ 32,000, which the authors found significantly different from estimates obtained in 
other studies conducted in different countries ($ 8,000‑50,000). The mean costs of medical 
care for CA until discharge, between those dead in hospital and those survived were $ 522 and 
$ 18,859, respectively. The mean healthcare cost during the 1‑year follow up was $ 12,953, 
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with the costs for inpatient care accounted for the majority of this amount. In 2017 Geri and 
colleagues [123] published a systematic review protocol on costs related to cardiac arrest 
management, underlining that in the developed countries, there is actually a wide variation 
in the approaches used to manage patients with CA, in both the prehospital care and after 
the patients are admitted to the hospital. In the hospital, the implementation of multifaceted 
interventions such as targeted temperature management or immediate coronary angiography 
with Percutaneous Coronary Intervention (PCI) in successfully resuscitated patients has led 
to greatly improved survival and health outcomes across countries, although this has come at 
a significant financial cost, which can limit a widespread adoption of technologies, potentially 
bearing to suboptimal results. The authors underlined that although there is some literature 
demonstrating the costs of individual components of care for CA, a comprehensive picture of 
all the costs associated with treating CA does not exist. This may be in part due to the com‑
plex, multidisciplinary care required by these patients. Furthermore, the available studies used 
different methods, perspectives, were performed in different healthcare systems, hence their 
results are not directly comparable.
We report below some results from the studies currently available.
In Germany, Graf et al. [124] investigated the costs and health status outcomes of In‑
tensive Care Unit (ICU) admission in patients after SCA with in‑hospital or out‑of‑hospital 
cardiopulmonary resuscitation. Out of 354 patients involved in the study, 31% were alive 5 
years after hospital discharge. Costs per hospital discharge survivor were € 49,952 including 
the costs of post‑hospital discharge. The total costs per Life Year (LY) gained were € 10,107. 
Considering 5‑year survivors only, the costs per LY gained corresponded to € 9,816, and those 
per QALY gained corresponded to € 14,487. Including 7 patients with severe neurological 
condition, costs per LY gained in 5‑year survivors increased by 18%, to € 11,566. The authors 
concluded that patients who leave the hospital following CA without severe neurological dis‑
abilities might expect a reasonable long‑term survival and quality of life compared with age 
and gender‑matched controls, at sustainable costs for the healthcare system.
In a study conducted in the Netherlands and published in 2004 [125], the authors calcu‑
lated the healthcare costs for the management of out‑of‑hospital CA related with the time to 
shock. Incremental CEA and Monte Carlo simulation was applied to compare scenarios of 
reduction in time to shock of 2, 4, and 6 minutes. Mean prehospital, in‑hospital, and post‑hos‑
pital costs in the first half‑year after CA were € 559, € 6,869 and € 666. Mean costs were € 
28,636 per survivor and € 2,384 per non‑survivor. Among patients shocked early (n = 24), 
46% survived, with costs averaging € 20,253. Of the intermediate group (n = 149), 26% sur‑
vived, with costs averaging € 31,467. Among patients shocked late (n = 135), 13% survived, 
with costs averaging € 27,781. The point estimates of the ICER of reduction of time to shock 
of 2, 4, and 6 minutes compared with baseline were € 17,508, € 14,303, and € 12,708 per life 
saved, respectively. Costs per survivor were lowest with the shortest time to shock because of 
shorter stay in the ICU.
The paper by Gage and colleagues [126] reports an estimate of health system resources 
used in the treatment of in‑hospital CA in a British district general hospital, considering both 
the resources used during the resuscitation attempts and during the post‑resuscitation phase 
in survivors observed during a prospective phase. The average variable cost per resuscitation 
attempt was £ 195.66; 76.5% was for staff, and 13.1% for drugs and fluids. The average fixed 
cost per resuscitation attempt was £ 928.81; 12% for capital equipment and 73% for staff 
training. The average post‑resuscitation costs attributable to the CA of the 29 people surviv‑
ing more than 24 hours after Cardio‑Pulmonary Resuscitation (CPR) were estimated to be £ 
1589.72. Eighty percent or more of the costs associated with resuscitation were attributable to 
the provision and maintenance of staff and physical capital. Length of stay was a crucial factor 
in post‑resuscitation expenditure.
As regards Italy, during 2006, a research project was initiated on SCD by the Centro 
Universitario di Studi in Amministrazione Sanitaria (CUSAS) and the Institute for internal 
medicine and cardiology of the University of Florence [77]. Among the study objectives, the 
authors estimated the socio‑economic impact due to LYs lost each year to SCD, using net 
individual median work salary for the basis of the calculation, ranging between € 6,482 mil‑
lion and € 12,216 million, each year. The Authors considered that half of the events occur in 
patients in whom, due to their high‑risk factor, SCD can be accurately predicted and avoided. 
Accordingly, they estimated the financial investment necessary to prevent SCD in at least 
these individuals, using the Disease Related Group (DRG) tariff as a proxy for the economic 
calculation of the procedure costs: an additional investment of € 310 million would have been 
necessary, representing the 0.33% of the national health budget in the year considered.
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DESCRIPTION OF THE TECHNOLOGY
The WCD can be considered an innovative addition to the spectrum of strategies for the 
prevention of SCD. The WCD is designed for patients at risk of SCD who are not immediate 
candidates for ICD therapy, and was granted FDA approval in the United States in 2001. In 
Europe, the LifeVest® was granted a CE mark for its first‑generation model, WCD 1, in 2000, 
and for the latest fifth generation, WCD 4000, in 2011. The indication for the LifeVest® refers 
primarily to patients aged 18 years or older, at risk of SCA, and who are not candidates for, 
or refuse an ICD. In the US, the FDA approved the WCD in 2015 for pediatric use in subjects 
aged 13 years or older who weigh at least 18.75 Kg and have a chest circumference of at least 
66 cm.
The WCD device consists of two main components: A) an electrode belt and garment that 
surrounds the patient’s chest, and B) a monitor that the patient wears around the waist or from 
a shoulder strap (Figure 2).
Washable garments are available in different sizes to suit most patients. The garment is 
worn around the chest of the patient. The monitor is attached around the waist or carried using 
the shoulder strap. The device’s electrodes are dry and non‑adhesive to provide patient com‑
fort. The monitor weighs about 1.4 pounds, making it lightweight and easy to wear. The heart 
of the patient is permanently monitored. The device contains pushbuttons and indicators for 
the user, as well as a speaker for sounding alarms and voice prompts. When the device detects 
a treatable arrhythmia, an alarm sequence begins, giving a conscious patient time to stop the 
treatment. If the patient holds the two “response” buttons at any time during the treatment 
sequence, the alarms will stop, and no shocks will be delivered. If the patient does not respond 
or releases the response buttons, the device continues to give alarms and verbal warnings to 
bystanders that a treatment shock is about to be delivered. Blue™ Gel within the electrodes is 
released just prior to delivering the treatment shock in order to avoid burns and to deliver the 
shock most efficiently. The entire event, from arrhythmia detection to delivery of the shock 
treatment, typically takes less than one minute. If a treatable arrhythmia persists after the first 
shock, up to 5 shocks may be given in a treatment sequence.
By providing automatic therapy, the WCD does not depend on a second person to defi‑
brillate, as required with a manual or AED. Unlike the ICD (including both transvenous and 
subcutaneous devices), the WCD requires no surgical operation, can be provided for a short 
period of time, is temporary, and is easily removed [34]. The patients need to wear the WCD 
all day and night long, except while taking a bath or shower.
The use of the WCD requires involvement of the patients, the cardiologist and the 
hospital and the manufacturer for service and maintenance. Patients need to be trained on 
how to use the WCD, and it can be helpful if a family member attends the training. Among 
the things to know, patients need to be made aware that a correct use of the technology 
requires them to follow a list of instructions on the daily changing and charging of the 
battery, on the washing of the garments, 
placing of the electrodes, and pressing the 
response buttons if prompted. Proper train‑
ing on the use of the WCD, especially in 
terms of compliance, is crucial for good 
outcomes.
The WCD is a rental device and is re‑
turned after patient use for cleaning and 
testing of the device, with reconditioning 
or repair completed when required. Devices 
must pass an inspection and testing process 
in order to be sent to another patient. ZOLL 
Medical Corporation has territory managers 
or agents in all the territories so that they 
guarantee a full service and delivery within 
48 hours. ZOLL gathers the data that is ab‑
solutely needed in order to provide service 
to the patient, more specifically, to provide 
24/7 technical support to the patient. Every 
patient is informed on what data is collected 
and the patient provides his/her written con‑
sent.
Figure 2. LifeVest® Device: A) electrode belt and garment that surrounds the 
patient’s chest, and B) monitor that the patient wears around the waist or from a 
shoulder strap
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Possible and potential indications for WCD use
We report below the list of possible and potential indications for the use of WCD accord‑
ing to Reek et al. [29].
Proposed indications:
 ‑ Acute MI with LVEF ≤ 35%;
 ‑ Before/after revascularization procedures (Coronary Artery Bypass Graft – CABG/PCI) 
with LVEF ≤ 35%;
 ‑ Recent onset cardiomyopathy NICM or presumed myocarditis with acute heart failure 
and/or LVEF ≤ 35%;
 ‑ Intermittent bridging after ICD removal (e.g., infection);
 ‑ Delayed but indicated ICD implantation;
 ‑ Bridge to heart transplantation;
 ‑ Genetic (e.g., Brugada, Long QT, Short QT, etc.) and congenital inherited heart diseases.
Potentially suitable indications:
 ‑ Period of risk stratification in cases with syncope/cardiac arrest of unknown origin; cases 
with suspected inherited arrhythmia syndromes;
 ‑ Protection in patients with Left Ventricular (LV) assist device;
 ‑ Potentially dangerous Electrocardiogram (ECG) changes with drugs (e.g., QT prolonga‑
tion).
However, since the present work focuses on post‑MI and ICD explanted patients, details 
are reported specifically on these subjects. After titles, abstracts and references lists from 
the full‑text publications were screened, we identified and reported in Table I all the eligible 
full‑text publications in which the WCD was used in the target conditions, i.e., patients after 
MI and or patients with ICD explant. Some papers focused on only these patients (specified as 
“post‑MI” or “explanted” in the “subjects” column), while others involved also patients with 
different conditions (identified as “Mixed indication”). We excluded from the present report 
all the publications in which we did not find information on the inclusion of post‑MI and/or 
ICD explanted patients.
Overall, we found documents from original researches reporting on efficacy and/or safety 
and/or compliance of WCD [5,7,8,11,15,17,18,20‑22,25,27,30,32,36,38,39,42,47,49,50,52‑5
4,57], two original researches were on CEAs using a decision model [37,41], a HTA [23], sev‑
eral literature reviews [6,10,12,13,16,19,26,28,29,33,43,44,48,50,55] a meta‑analysis [9], and 
guidelines [14,35,40], recommendations [34], consensus [45,46,56] a letter to the editor [31] 
and an editorial [24]. Generally, the main messages reported in these publications are that the 
WCD shows to be beneficial in patients with appropriate indications. The WCD can benefit 
patients in primary prevention, e.g., in patients after an acute MI, and for secondary preven‑
tion, i.e., in patients who survived SCA or sustained Ventricular Fibrillation (VF)/ Ventricular 
Tachycardia (VT), when the underlying cause might be treated or an implantation is impossi‑
ble due to comorbidities or with ICD explant when immediate reimplantation is not possible. 
Because of its strict relationship with effectiveness, attention is to be paid to compliance, 
which might not be optimal in all patients. Taking into consideration patients’ preferences 
and investing in good patient training can enhance the compliance rates. Finally, despite the 
many observations from real world use are useful, several authors underline the importance of 
conducting further research to gain evidence also from randomized controlled trials.
Overall, 5 publications focused on post‑MI patients [5,15,38,41,49], 5 on ICD explanted 
patients [20,21,37,47,56] and the other 45 publications involved subjects with mixed diagno‑
ses.
EFFECTIVENESS, SAFETY AND COMPLIANCE OF WCD 
IN PATIENTS WITH MI OR WITH ICD EXPLANT
In order to report details on effectiveness, safety and compliance on post‑MI and ICD 
explanted patients, we further selected from Table I and describe in Table III the main charac‑
teristics of the original research in which these patients were involved, and their main demo‑
graphic and clinical characteristics.
In total, 26 original researches were found, of which 4 focus on patients with MI 
[5,15,38,49] and 3 focus on those with ICD explant [20,21,47], while 19 (73%) studies evalu‑
ated the use of the WCD across various indications, specified as “mixed” [7,8,11,17,18,22,25
,27,30,32,36,39,42,50‑54,57].
Fifteen out of 26 studies were performed in the US and EU [5,7,8,17,20,21,25,39,47,49,51
‑54,57], 9 in European Countries [11,15,18,22,27,36,38,50,57], 2 in Japan [30,42],1 in Austra‑
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lia [32] and 1 in Israel [17]. No study was performed in, or included data from Italy. Overall, 
the observation was on data occurring from 2002 until 2017. Generally, all these studies cov‑
ered aspects on effectiveness and/or safety and/or compliance and/or on optimization of WCD 
use in different indications and contexts. Eighteen studies were retrospective [7,8,18,20,21,
25,27,32,36,38,42,47,49,50,51‑54], and 7 studies were prospective [11,15,17,22,30,39,57]. 
One study was a multicenter, randomized, controlled trial where eligible participants with a 
previous MI were randomly assigned in a 2:1 ratio to receive a WCD plus guideline‑directed 
medical therapy (the device group) or to receive guideline directed medical therapy alone (the 
control group), at hospital discharge [5].
Tables IV and V show details on effectiveness and/or compliance found from the studies 
involving only patients with MI or with ICD explant, respectively. We did not find overlap‑
ping of participating subjects between these studies. Overall, the selected studies included a 
highly variable number of participants: overall, we found that patients with MI were 12,916 
in total, and those with ICD explant were 10,169 in total. We note that the number of target 
patients was not specified in 3 studies performed on patients with MI [17,51,57].
Importantly, most of the studies with mixed samples reported results only in their full 
study sample, hence it was possible to gather specific results on our target patients from few 
studies. Furthermore, the studies described are difficult to compare because of differences in 
study designs, definitions of patients and observational periods. For instance, despite the fact 
that all studies were performed on patients who experienced MI, cohorts of the subjects were 
heterogeneous, since different characteristics of the study samples were adopted, e.g., in terms 
of LVEF (≤ 40%, 30% or 35%), time from MI event or revascularization for MI, follow‑up 
(from 6 days to 2.6 years), etc. Accordingly, it was difficult to compare the results between the 
selected studies. Nevertheless, a general agreement was found from these studies, i.e., patients 
with MI at high risk of SCD may benefit from WCD therapy, which could be useful for pre‑
venting arrhythmic death and for optimizing guideline‑driven ICD implantation, or to be used 
as a bridge to transplantation or ICD implantation in patients with appropriate indications.
Below we describe the main results of the 4 original researches [5,16,38,49] focusing on 
patients with MI occurring within 3 months.
The most recent study is the VEST randomized clinical trial conducted in the US by Ol‑
gin and colleagues [5]. It involved patients hospitalized for an acute MI and with EF <35%, 
discharged from hospital up to 7 days earlier. The patients were randomly assigned to receive 
WCD plus guideline‑directed therapy (the device group involving 1524 patients) or to receive 
only guideline‑directed therapy (the control group involving 778 patients). Participants in the 
device group wore the device for a median of 18.0 hours per day (interquartile range, 3.8 to 
22.7). Arrhythmic death occurred in 1.6% of the participants in the device group and in 2.4% 
of those in the control group (relative risk = 0.67; 95% CI = 0.37‑1.21; p=0.18). Death from 
any cause occurred in 3.1% of the participants in the device group and in 4.9% of those in 
the control group (relative risk = 0.64; 95% CI = 0.43‑0.98; uncorrected p=0.04), and non‑ar‑
rhythmic death in 1.4% and 2.2%, respectively (relative risk = 0.63; 95% CI = 0.33‑1.19; 
uncorrected p=0.15). Of the 48 participants in the device group who died, 12 were wearing 
the device at the time of death. A total of 20 participants in the device group (1.3%) received 
an appropriate shock, and 9 (0.6%) received an inappropriate shock. Among the participants, 
25 reported adjudicated arrhythmic death, 9 were wearing the WCD at the time of death, 4 of 
whom received appropriate shocks and 5 of whom had no ventricular tachyarrhythmias. In 
order to assess impact of wearing the WCD on sudden death, non‑arrhythmic death, and total 
mortality, an “as treated” analysis was performed in the VEST trial to assess event rates per 
100 person‑months of wearing the WCD compared to not wearing the WCD and compared 
the two rates using Poisson regression. Based on this analysis, the VEST trial reported a total 
mortality rate of 0.50 per 100 person‑months of patients wearing the device, and 1.91 per 100 
person‑months of patients not wearing the device, reporting a higher efficacy of VEST (rate 
ratio = 0.26; 95% CI = 0.14‑0.48; Bonferroni corrected p<0.001). A study conducted in France 
[15], reported that WCD was life‑saving in one patient (1/24) with prompt defibrillation shock 
delivery. During a mean wearing period of 3.0 ± 1.3 months, two episodes of VA occurred 
in two patients (8.3%): one successfully treated with WCD shock and one with spontaneous 
termination. The mean and median daily use of the WCD in these patients was 21.5 hours and 
23.5 hours a day, respectively. The Authors’ conclusions were that a high rate of VA occurred 
during the early period following myocardial revascularization with PCI in patients with low 
LVEF. The WCD was life‑saving in 1 patient, considering also who used it <10 hours per day.
Kondo et al. [38], in their study conducted in Germany, analyzed the effectiveness of the 
WCD therapy in early post‑MI patients. The median length of use was 33 days (20‑67 days), 
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Results
and the median daily WCD use was 23.1 h/day (range: 21.6‑23.6 h/day). The use of WCD 
contributed to the goal of optimized guideline‑driven ICD implantations, avoiding 42% (10 
patients) of unnecessary devices. None of the patients died during the WCD therapy; how‑
ever, two patients (8.3%) had a fatal non‑arrhythmic event within 3 months after MI. The 
authors concluded that the WCD contributed to the goal of optimized guideline‑driven ICD 
implantations. Furthermore, according to the opinion of most patients, the device was easy to 
handle after sufficient training before receiving the device.
Epstein et al. [49] from US retrospectively assessed the benefit of WCD use in 8,453 
patients, from the database maintained by the manufacturer for American regulatory. Median 
daily use of WCD was 21.8 h per day and the mean length of use was 69 ± 61 days (median 
57 days). In total 133 (1.6%) patients were appropriately treated with WCD and received 
309 (3.7%) appropriate shocks (1.6%) with a resulting survival of 95% in revascularized and 
84% in non‑revascularized patients. The rate of inappropriate treatment was <1%. Ninety‑six 
percent of the patients received the shock in the first 3 months of WCD therapy and 75% in 
the first month.
The actual survival analysis of all patients treated with a WCD showed that in the 3‑, 6‑, 
and 12‑month intervals following WCD application, cumulative survival was 96%, 94%, and 
93%, respectively, while for patients treated with appropriate shocks in the same 3‑, 6‑, and 
12‑month intervals, cumulative survival was 73%, 70%, and 65%, respectively. The authors 
concluded that 1.4% of patients may be successfully treated in the first 3 months with a resus‑
citation survival rate of 91%, implying that a select group of patients may benefit from defi‑
brillation early after MI, particularly during the first 30 days following hospital discharge. The 
WCD may benefit individual patients selected for high risk of SCA early post‑MI, particularly 
during the first 30 days following hospital discharge.
Results on WCD in patients undergoing ICD explant are reported in Table V. Overall, 
these studies recognized that the WCD could prevent SCD in patients who underwent ICD 
removals for CDI, however their results appeared difficult to compare and synthesize in terms 
of outcomes. Only 3 studies [20,21,47] were restricted to patients who were discharged after 
ICD removal, described below.
Castro and colleagues [20] reported data on WCD use in 24 German patients, who un‑
derwent ICD or Cardiac Resynchronization Therapy‑Defibrillator (CRT‑D) removal due to 
device‑related local or systemic infections, during 392 ± 206 days. In contrast to previous 
published data by Tanawuttiwat et al. and Chung et al. [47,53], the authors observed no inap‑
propriate shocks in their study. However, consistent with other studies [39,47,53], the mean 
daily wear time was 22.0 (15‑24) hours. Castro and colleagues concluded that the WCD was 
a safe, comfortable and cost‑effective bridging solution for the observed patients, with a sur‑
vival rate of 100% and no recurrent device infection after a mean follow‑up time of 454 days 
[20].
The biggest cohort of patients with ICD explant were reported from Ellenbogen et al. 
(n=8,058) [21]. While wearing the WCD, 334 patients (4%) experienced 406 VT/VF events, 
of which 348 events were treated. Shocks were averted in 54 VT/VF events by conscious 
patients. A low inappropriate shock rate was reported, similar to other studies [39]. After ICD 
explant, 78% of patients used the WCD for up to 3 months. Of the 22% who continued wear‑
ing the device after 3 months, 6% continued beyond 6 months, and 1% continued to use the 
WCD for more than 1 year. Previously published articles reported a mean length of use in all 
WCD patients of about 2 months [53]. Conclusions by Ellenbogen and colleagues [21] are 
that the WCD was effective against VT/VF mortality, with a low incidence of unnecessary 
shocks. Clinicians used the device as a short‑term (up to 12 weeks) solution for SCA protec‑
tion in the majority of patients, although 22% of patients used the tool for longer terms (>3 
months). This device can offer clinician’s flexibility in managing post‑ICD explant patients 
during a vulnerable period until a long‑term risk management strategy can be implemented.
Tanawuttiwat et al. [47] performed a retrospective study in patients who underwent ICD 
removal due to cardiac device infections at two American referral centers. Clinical character‑
istics and device information on 97 patients were analyzed. The median daily WCD use was 
20 hours/day and the median length of use was 21 days. Three patients were shocked by the 
WCD: 2 patients had four episodes of sustained VT, successfully terminated by the WCD, 
while the third patient experienced two inappropriate treatments due to oversensitivity of the 
signal artifact. Three patients experienced sudden death outside the hospital while not wear‑
ing the device. Five patients died while hospitalized. The authors concluded that the WCD 
is useful in protecting patients during the gap between ICD removal and reimplantation. The 
mortality in this case series was 8.2%. All deaths occurred when the WCD was not in use; 
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ECONOMIC IMPLICATIONS OF WCD
In the context of constrained health care resource availability, it is important to assess the 
ratio between costs and effectiveness, as well as to identify the driving factors that influence 
the upper and lower bounds of sensitivity when evaluating the use of WCD therapy in patients 
who are at risk of SCD and SCA. The results of economic studies will be useful for health 
policy and access stakeholders making reimbursement and funding decisions.
We found 4 studies assessing the cost and cost‑effectiveness of WCD use, published be‑
tween 2015 and 2017. Overall, the WCD reported a good value for money. However, some 
differences in the results of the available studies can be explained by the fact that different 
methods were used, heterogeneous populations were involved and they were conducted in 
different settings, using different perspectives, different time horizons and analyzing different 
types of data.
Among the main differences, 1 study was targeted to subjects with ICD explant [37], 1 
focused on patients with early MI [41], while the other 2 studies involved subjects with dif‑
ferent indications including cases of ICD explant due to infection and those who are early 
post‑MI [27,32].
The two studies by Healy & Carrillo [37] on patients who underwent ICD removal and by 
Sanders et al. [41] on early post‑MI patients, were conducted using a Markov economic model 
applied in the US healthcare system, adopting the perspective of the society [37] and the 
perspective of Medicare [41]. Accordingly, Healy & Carrillo [37] analyzed direct costs (e.g., 
cost of the WCD device, hospital costs, cost of laboratory tests, cost of follow‑up visits and 
costs related with ICD implantation and management) and indirect costs (loss of income and 
loss of productivity for premature death), while Sanders et al. [41] included only direct costs. 
A lifetime simulation period was considered in the model. Healy & Carrillo [37] estimated 
the cost effectiveness of the WCD in patients who underwent ICD explant and were deemed 
to require reimplantation due to SCA risk but in whom immediate reimplantation was not 
possible. For these patients, the authors assumed 4 management options: 1) discharge home 
with WCD until reimplantation; 2) discharge home without WCD until reimplantation; 3) dis‑
charge to a Skilled Nursing Facility (SNF) without a WCD until reimplantation; and 4) remain 
in the hospital without WCD until reimplantation. The efficacy of alternatives was reported 
in terms of SCA mortality, non‑SCA mortality and post‑reimplantation mortality. QALYs and 
LYs gained were used as parameters of effectiveness between the alternative strategies. In the 
analysis by Healy & Carrillo, the ICER of the WCD strategy, compared to discharge home 
without a WCD was $ 20,300 per LY or $ 26,436 per QALY gained [37]. In the other options, 
instead, no deaths occurred while a WCD was worn. Compliance in general was acceptable. 
Three SCA events occurred in one patient, and one conscious sustained VT occurred in an‑
other. Both were successfully treated with a shock by the WCD.
A further aspect to be considered as a possible benefit of the WCD is the potential capabil‑
ity to improve the selection of patients suitable to ICD Implantation. For instance, in Kutyifa 
and colleagues [39] showed a proportion of 40% of patients that did not need an ICD after the 
evaluation phase with the WCD.
An important aspect to be considered regarding WCD treatment is the patients’ compli‑
ance, which can significantly influence the effectiveness. Generally, in the selected papers, we 
found positive findings on compliance, although it was not found very satisfactory in all of 
them [16,53]. For instance, Chung et al. [53] found that half of the patients wore the defibril‑
lator continuously. Instead, according to other authors [16], patient education by specialized 
health caregivers can help to achieve good compliance to therapy, since patient’s compliance 
with the WCD is closely linked to the understanding and knowledge of their cardiac disease 
as well as potential benefits associated with the appropriate use of the device. Appropriate 
training and education of the patient on how to properly wear the WCD, change the battery 
and respond to device alarms is a crucial part of the patient’s education.
Overall, good compliance rates were found especially in recent studies: e.g., the median 
daily wear time was 23.1 and 22.5 hours from the observation of patients involved in regis‑
tries [36] and [39], respectively. This may be the result of increased comfort seen with newer 
generations of WCDs, which are smaller and weigh less than the initial WCDs used in earlier 
studies. 
Finally, details on safety are reported in Table VI, which shows that few results were found 
from the literature on safety related with the use of WCD by subjects with MI or with ICD 
explant.
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discharge home with WCD versus discharge to a SNF without WCD and versus in‑hospital 
stay without WCD, was dominant; since WCD was less costly and more effective than al‑
ternatives. One‑way and two‑way sensitivity analyses were performed to account for result 
uncertainties. SCA event rate, WCD treatment efficacy and time to reimplantation had the 
highest impact on the ICER. Overall, WCD cost effectiveness decreased as SCA event rates 
decreased. The WCD cost effectiveness is also positively impacted by higher WCD efficacy. 
The ICER ranged between $ 15,392/QALY and > $ 50,000/QALY if the WCD efficacy of 
95% and <69% was considered, respectively. Further, with regard to time to reimplantation, 
the WCD remained cost‑effective, considering 5.6% 2‑month SCA risk, as long as the time to 
reimplantation was at least 2 weeks.
Similar to the previous one, another study explored the cost‑effectiveness of WCD in early 
post‑MI patients [41]. The model tracked a cohort of patients during their lifetime who were 
considered at an increased risk for SCD but not yet eligible for prophylactic ICD implanta‑
tion since they were within either 40 days from their MI or 90 days from coronary revascu‑
larization. Patients received either the WCD or current standard of care (no therapy). The 
authors included directs costs associated with WCD use, emergency medical services, ICD 
implantation and follow‑up. They assumed $ 2,754/month for WCD patients and an addi‑
tional physician visit for patients who received an inappropriate shock. A cost of $ 18,500 for 
patients within the standard of care strategy and subsequent hospitalization was considered. 
Additional costs related to ICD implantation ($ 36,034), generator replacement ($ 27,271), 
and lead replacement ($ 15,595) were included. The model results were reported in terms 
of costs, quality of life, survival and the incremental cost‑effectiveness of WCD, compared 
with usual care. In the Sanders analyses, the WCD strategy was more expensive than usual 
care (incremental cost of $ 11,503), but improved life expectancy by 0.261 life years or 0.190 
QALYs. The incremental cost effectiveness of the WCD was $ 44,100/LY or $ 60,600/QALY.
The authors explored the sensitivity of model predictions to uncertainty in model param‑
eters in sensitivity analysis, using ranges of values for key parameters. Overall, the ICER of 
WCD was more favorable in higher‑risk patients. With higher probability of SCA, the WCD 
was more cost effective. Use of the WCD cost < $ 100,000/QALY gained as long as the rate of 
cardiac arrest in the first month post‑MI was > 1.16%. This suggests that patients at low risk 
of SCA would be unlikely to obtain sufficient benefits from the WCD. The efficacy of WCD 
in successfully terminating SCA events is another model parameter of key importance. The 
use of the WCD costs less than $ 100,000/QALY, even if the WCD was only successful in 
terminating 80% of events. The authors concluded that use of a WCD could reduce the rate of 
SCD during the recovery period of patients who have had a recent MI and have reduced left 
ventricular function at a cost that appears to be economically attractive when compared with 
other generally accepted treatments in the US [41].
In the Netherlands, Quast et al. described the costs of WCD therapy in 79 patients. How‑
ever, the population was heterogeneous: newly diagnosed cardiomyopathy was reported in 
58.2% of patients and the remainder (42.8%) had an indication for device extraction due to 
ICD infection or other reasons [27].
A previous study was conducted in Australia and reported some considerations on the cost 
of WCD. The study included only 8 patients with a wide range of indications for WCD use. 
Of these patients, 3 suffered a device infection, 3 suffered a cardiomyopathy, 2 patients had 
myocarditis and aortic stenosis, respectively [32].
The small sample size and the heterogeneity among patient indications makes it difficult 
to generalize results from one study to another. The benefits of WCD are dependent on patient 
selection [29]. Therefore, other analyses in selected populations are strongly needed to dem‑
onstrate the true benefits and to secure a cost‑effective use of WCD.
No specific economic evaluations for the Italian setting were retrieved by the literature re‑
view. To fill this gap, two decision analytical models were developed to estimate the economic 
implications attributable to the use of WCD in target patients with post‑MI (Model 1) and 
target patients with ICD explant for an infectious indication (Model 2). A Cost Effectiveness 
Analysis (CEA) was performed with Model 1, to estimate the Incremental Cost Effectiveness 
Ratio (ICER) attributable to the use of WCD in post‑MI patients, since the WCD showed to 
be more effective and more costly than standard care. The ICER shows the incremental cost 
per unit of additional effectiveness attributable to the use of WCD in the target patients. A 
Cost Minimization Analysis was performed with the Model 2, assuming an equivalent effec‑
tiveness between the WCD and the standard of care in Italy (hospitalization in a low intensity 
hospital after ICD removal) among patients with ICD explant due to infection. Under this 
assumption, we do not include clinical consequences but only economic consequences in 
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the model, in order to estimate the difference in costs between WCD and standard of care in 
target patients. This is a conservative approach because “Hospitalization in a low intensity 
hospital” does not guarantee that patients are adequately protected from SCD unless they are 
on a monitored bed.
Both the models were performed simulating a lifetime time horizon and adopting the point 
of view of the Italian National Health Service (NHS). The data used to populate the models 
were obtained from the extensive literature research conducted for this HTA and from a spe‑
cific literature research based on the data required by the models.
Cost effectiveness of WCD used in patients with MI in Italy
We developed a decision‑analytic Markov model to assess the cost‑effectiveness of the 
WCD compared with the current standard of care for post‑MI patients. The decision‑analytic 
model simulated the period of 90 days where the WCD is used and the patients are not yet 
eligible for prophylactic ICD implantation. The Markov model simulated the period after the 
90 days post‑MI, including the effect of ICD, in which patients were followed whose LVEF 
had improved to >35% treated with optimal medical therapy. Patients with an LVEF ≤35% 
had an ICD implanted for primary prevention. During the simulation, patients were at risk 
of dying and this risk decreased based on ICD therapy. Patients who had an ICD implanted 
were at risk for ICD infections, lead failure, explants, inappropriate shocks and subsequent 
hospital stays, as well as the need for generator replacements over time. The model assessed 
patient survival, their HRQoL, and the costs related to their state of health. From the model 
we estimated the (ICER) of WCD use vs standard of care expressed as € per Quality Adjusted 
Life Year (QALY) gained.
Study Design
We developed a decision‑analytic model to estimate the lifetime costs and benefits of 
WCD versus medical therapy alone at hospital discharge in patients who had been hospital‑
ized with an acute myocardial infarction with a left ventricular ejection fraction (LVEF) of 
35% or less (assessed ≥8 hours after myocardial infarction).
To build the model, we used the data from the recent VEST randomized clinical trial [5]. 
When data necessary to build a model appropriate for our healthcare system were not avail‑
able, we used other published and referenceable sources of data (Table VII).
We discounted costs and benefits at an annual 3% rate [127,128] and performed the analy‑
sis from the perspective of the Italian National Health Service (NHS). We expressed out‑
comes in terms of 2018 euro (€), life‑years (LYs), quality‑adjusted life‑years (QALYs), and 
incremental cost‑effectiveness ratios (ICERs) expressed as € per LY gained and € per QALY 
gained.
Decision‑Analytic Model
We built a state‑transition Markov model to assess the overall outcomes associated with 
the use of WCD, using a lifetime time ho‑
rizon and monthly cycle (Figure 3). A hy‑
pothetical cohort of patients post‑MI was 
considered, using the data from the recent 
VEST randomized clinical trial [5]. Accord‑
ingly, the cohort under study had a mean 
age of 61 years, received the WCD or only 
a medical therapy at hospital discharge. Pa‑
tients stayed in this health state for 3 months 
or received an implantable cardioverter defi‑
brillator (ICD) before the end of this period 
if a condition requiring an ICD was devel‑
oped. After 3 months, patients who were 
alive and had not already received an ICD, 
were re‑evaluated to determine their eligibil‑
ity for a primary prevention ICD implanta‑
tion (LVEF≤35%) or for only medical ther‑
apy (LVEF>35%). ICD implantation could 
be successful or result in procedural death. 
Patients who had received an ICD entered 
in the post‑ICD health state in which they 
Figure 3. Markov model for cost-effectiveness evaluation in post MI
EF = Ejection Fraction; HF = heart failure; ICD = Implantable Cardioverter Defibrillator; 
MI = Myocardial Infarction; WCD = Wearable Cardioverter Defibrillator
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could become hospitalized for heart failure, experience lead failure, ICD infection, ICD gen‑
erator replacement or die for cardiac death or other causes. Patients with LVEF>35% who had 
received only medical therapy entered in the No‑ICD health state where they could die for 
cardiac death or other causes. We constructed the model by using Microsoft Excel.
Efficacy
In the base case (VEST ITT) scenario, using the ITT data reported in the VEST trial [5], 
we modeled the efficacy of WCD on the basis of the overall survival at 90 days: 3.1% in the 
WCD group and 4.9% in the medical therapy. We used these data to estimate the monthly 
probability of death in the patients treated with WCD and in the patients treated with medical 
therapy alone (Table 7). We also determined the risk of receiving an ICD before the 90 days, 
based on VEST trial: 4.4% in the WCD group and 5.7% in the medical therapy group, even 
if it was forbidden by the VEST trial protocol, apart from secondary prevention (Table VII).
Mortality and adverse events
In the 90 days post‑MI, we accounted for all‑cause mortality using the VEST trial [5], 
considering the short time horizon and the possible misclassification bias associated to the 
definition of cause of death in medical therapy group within the trial. The VEST trial was also 
used to estimate the WCD risk of inappropriate shock (Table VII).
While for the long‑term mortality associated to a patient after 90 days post‑MI, we sepa‑
rately modeled non‑cardiac and cardiac death respectively, following the approach used by 
Woo et al. [143]. Because the risk for death from general (non‑cardiac) causes increases with 
age, we separated the risk for death into general population and excess cardiac components. 
We based our general population mortality on the age specific risks for death from the Italian 
National Institute of Statistics [144]. In the patients who received an ICD, the excess of cardi‑
ac mortality (Table 7) was estimated based on the overall mortality in the ischemic ICD group 
of SCD‑HeFT (Sudden Cardiac Death in Heart Failure) Trial [131] and on the prevalence of 
cardiac death in the MADIT‑II (Multicenter Automatic Defibrillator Implantation Trial) [132]. 
In the patients without ICD, the excess of cardiac mortality (Table VII) was estimated based 
Parameter Value References
Cohort mean age (years) 61 Olgin 2018 [5]
Discount rate of efficacy 0.030 Sanders 2016 [127], Cortesi 2018 [128]
Discount rate of cost 0.030 Sanders 2016 [127], Cortesi 2018 [128]
90 days post MI with WCD
Mortality – monthly probability 0.0104 (0.0084‑0.0125) Olgin 2018 [5]
Inappropiate shock – monthly probability 0.002 (0.0016‑0.0024) Olgin 2018 [5]
ICD implantation within 90 days post‑MI – monthly probability 0.0149 (0.0119‑0.0178) Olgin 2018 [5]
Probability EF ≤35% at 90 days 0.4070 (0.3256‑0.4884) Sjoblom 2014 [129]
90 days post MI with Medical therapy
Mortality – monthly probability 0.0166 (0.0133‑0.0199) Olgin 2018 [5]
ICD implantation within 90 days post‑MI – monthly probability 0.0194 (0.0155‑0.00232) Olgin 2018 [5]
Probability EF ≤35% at 90 days 0.4070 (0.3256‑0.4884) Sjoblom 2014 [129]
ICD
Procedural death – monthly probability 0.0020 (0.0016‑0.0024) van Rees 2014 [130]
Cardiac mortality in patients with ICD – monthly probability 0.0044 (0.0035‑0.0052) Bardy 2005 [131], Greenberg 2004 [132]
Probability of lead failure – monthly probability 0.0015 (0.0012‑0.0018) Kremers 2013 [133]
Probability of ICD infection – monthly probability 0.0007 (0.0006‑0.008) Kremers 2013 [133], Uslan 2007 [134], 
Margey 2010 [135], Johansen 2011 [136]
Death from lead failure – monthly probability 0.0130 (0.0104‑0.0156) Cheng 2010 [137]
Death from ICD infection 0.0500 (0.0400‑0.0600) Margey 2010 [135], Sohail 2007 [138]
Battery life (replacement) 0.0113 (0.0091‑0.0136) Kramer 2013b [139], Gandjour 2011 [140]
Hospitalization for HF 0.0080 (0.0064‑0.0096) Moss 2009 [141], Tang 2010 [142]
No ICD
Cardiac mortality in patients without ICD – monthly probability 0.0019 (0.0015‑0.0022) Solomon 2005 [87]
Table VII. Clinical data input for cost-effectiveness model on post MI
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on the patients with LVEF >30% of VALIANT (Valsartan in Acute Myocardial Infarction 
Trial) [87]. We held the excess cardiac mortality constant while allowing the general popula‑
tion mortality to rise with age; cardiac death therefore comprised a gradually decreasing frac‑
tion of the overall risk for death.
Further, we included in the model a risk of death associated to ICD implantation and ICD 
adverse events (lead failure and ICD infection) [135,137,138,145]. We obtained the probabili‑
ties of lead failure, ICD infection based on published registry data [134‑138,146].
Costs
In the first 90 days of the simulation, we included WCD cost and overall cost associated 
to post‑MI patients based on a study of MI economic burden conducted on an administrative 
Italian database [147] (Table VIII). This study reported a cost per patient‑month post MI of € 
760 (excluding the cost of the index event hospitalization) in the first year that decreased to 
€ 327 per patients‑month in the 2nd and 3rd year post MI. For both WCD and medical therapy 
treatment simulated, we assumed the same monthly cost considering no difference in the 
medication use and rehospitalizations reported in the VEST trial for both arms. In the WCD 
simulation we also account for the cost associated to the use of WCD, € 10,800 for the first 90 
days after MI, based on the Italian mean price provided by ZOLL.
For the ICD implantation and the related interventions associated to ICD adverse events, 
we applied the cost associated to the appropriate Italian DRG (Table VIII) [148]. The same 
approach was used to estimate the cost associated to HF hospitalization in ICD patients.
We estimated the expected battery lives of ICD devices according to previously reported 
data [139], assuming a mean battery life of 5 years and assuming no battery failure in the first 
2 years after ICD implantation [140]. For patients with or without ICD, we associated the 
mean monthly costs associated to patients after MI based on a study of MI economic burden 
conducted on an administrative Italian database (Table VII) [147].
Because the utility value decreases with age, we based our utility value on the age specific 
utility from the EQ‑5D utility score reported for the Italian population [149]. In the model, the 
utility values associated with the age‑specific Italian general population were adjusted based 
on the disutility values associated to the health states and events simulated.
Parameter Value References
Costs (€)
WCD – monthly cost 3,600 (2,894‑4,306) Assumption
Monthly cost in the 90 days after MI with WCD 761 (609‑914) Mantovani 2011 [147]
ICD implantation 16,573 (13,258‑19,888) DRG 515 – G.U. 2013 [148]
ICD replacement 16,573 (13,258‑19,888) DRG 515 – G.U. 2013 [148]
Revise due to lead problem 3,547 (2,837‑4,256) DRG 515 – G.U. 2013 [148]
Revise due to infection 16,573 (13,258‑19,888) DRG 515 – G.U. 2013 [148]
Monthly cost after ICD implantation 327 (261‑391) Mantovani 2011 [147]
HF hospitalization 4,898 (3,918‑5,878) D'angiolella 2019 [151]
Monthly cost after 90 days post‑MI without ICD 327 (261‑391) Mantovani 2011 [147]
Utility
Disutility WCD 0.050 (0.040‑0.060) Assumption
Disutility MI 0.0626 (0.0501‑0.0751) Borisenko 2015 [150]
Disutility inappropriate shocks1 0.5 (0.4‑0.6) Sanders 2015 [41]
Disutility ICD surgery 0.0164 (0.0131‑0.0197) Smith 2013 [152]
Disutility lead failure2 1.0 Woo 2015 [143]
Disutility ICD infection3 1.0 Woo 2015 [143]
Disutility ICD replacement 0.0164 (0.0131‑0.0197) Smith 2013 [152]
Disutility HF hospitalization4 0.4830 (0.3864‑0.5796) Woo 2015 [143]
Disutility post ICD 0.1167 (0.0187‑0.2157) Borisenko 2015 [150]
Disutility post‑no ICD 0.0368 (0.0294‑0.0442) Borisenko 2015 [150]
Table VIII. Cost and utility data inputs for cost-effectiveness model on post MI
1 Apply for 0.5 (0.4‑0.6) days
2 Apply for 2 (1.8‑2.2) days
3 Apply for 5 (4‑6) days
4 Apply for 12 (9.6‑14.4) days
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Results
For the patients in the first 90 days post‑MI, we used the disutility associated to MI [150] 
with an additional disutility for the patients with WCD based on the inappropriate shock 
events and on a conservative assumption on the impact of WCD in daily life (Table VIII). In 
the patients who received an ICD after 90 days, we assumed a disutility associated to ICD 
implantation, ICD lead failure, ICD infection, and hospitalization for HF and ICD battery 
replacement (Table VIII). The ICD disutility data and approach for their estimations were 
retrieved from the study by Woo et al. [143].
For patients in the post‑ICD health state, we assumed the disutility associated to heart fail‑
ure, while for the patients with no ICD, we assumed the disutility value associated to post‑MI 
due to a better LVEF associated to this patient (Table VIII) [150].
Analysis
A base case (VEST ITT) analysis was performed based on the results of the ITT analysis 
of VEST trial [5] and on the data input and assumption described above, while an alternative 
scenario was assessed as a sensitivity analysis to address the impact of WCD cost, reducing 
and increasing the 90‑day WCD cost from ‑30% to +30%.
Finally, we performed a one‑way sensitivity analysis to assess the impact of each param‑
eter (Table VII and Table VIII) on the model results and a probabilistic sensitivity analysis to 
account for the influence of simultaneous changes in correlated and uncertain model inputs 
on the cost‑effectiveness of WCD. In the probabilistic analysis, we randomly sampled model 
inputs from distributions based on their expected values and uncertainty distributions derived 
from a literature review and clinical judgment and ran 1,000 independent simulations to esti‑
mate the probability that WCD would meet a particular willingness‑to‑pay threshold.
Results
In the base case (VEST ITT) scenario l, the WCD was the most effective yet the more 
costly treatment with 0.19 QALYs gained compared to Medical therapy and an incremental 
cost of € 9,048 per patient. (Table IX) The ICER estimated was € 47,709 per QALY gained 
that is lower than the highest cost‑effectiveness threshold (€ 60,000 per QALY gained) re‑
ported in the economic‑evaluation conducted in Italy [153‑156]. In the base case (VEST ITT), 
the WCD also reported an improvement of 0.24 LYs compared to Medical therapy. Based on 
the improved survival, and on the incremental cost of € 9,048 per patient, the WCD reported 
an ICER of €38,276 per LY gained.
Another scenario assessed in the analysis was the impact of WCD price on cost‑effective‑
ness results (Figure 4). In this analysis, we observed a linear relationship between ICER and 
WCD price, with an ICER range from around € 37,000 to € 58,000 per QALY assuming a 
WCD cost from € 2,700 to € 4,500 per month.
Besides WCD costs, the other parameters with a higher impact on cost‑effectiveness re‑
sults were mortality at 90 days in WCD and medical therapy treatments and the probability 
of ICD implantation before 90 days, as shown by the one‑way sensitivity analysis (Figure 5). 
Based on these results, the cost‑effectiveness of WCD could be higher in the base‑case (VEST 
ITT) scenario considering the higher rate of ICD implantation before 90 days observed for 
the patients without WCD in the clinical practice compared to what was reported in the VEST 
trial, where participants were prohibited from receiving an ICD before 90 days [38].
A cost‑effectiveness acceptability curve was also estimated. The cost‑effectiveness ac‑
ceptability curve (CEAC) is a graphical method for summarizing the impact of uncertainty 
on the results of an economic evaluation, frequently expressed as an ICER or willingness to 
pay. The CEAC, derived from the joint distribution of costs and effects, illustrates the Bayes‑
ian probability that the data are consistent in relation to possible values of the cost‑effective‑
ness threshold.
Figure 6 shows that in the case of the WCD, given a maximum acceptable ratio of € 
60,000, the probability that the WCD therapy is cost‑effective compared with routine medi‑
cal treatment is 0.55. This is equivalent to stating that, given the data, there is a 55% chance 
that the additional cost of WCD therapy, compared with routine medical management, is less 
than the willingness to pay threshold of € 60,000 per QALY gained reported in the econom‑
ic‑evaluation conducted in Italy [153‑156]. Note the comparative nature of both statements. 
It is not equivalent to stating that the WCD therapy has a 55% chance of costing less than € 
60,000.
Cost (€) Cost d (€) LYs LYs d QALYs QALYs d
WCD
97,961.78 76,808.64 15.78 11.71 12.95 9.65
Medical therapy alone
88,566.24 67,759.84 15.46 11.48 12.69 9.46
∆ Cost (€) ∆ Cost d (€) ∆ LYs ∆ LYs d ∆ QALYs ∆ QALYs d
WCD vs Medical therapy alone
9,395.53 9,048.80 0.33 0.24 0.26 0.19
ICER € x Lys (€) ICER € x Lys d (€) ICER € x QALY (€) ICER € x QALY d (€)
27,786.84 38,275.53 34,245.49 47,709.07
Table IX. Base-case (VEST ITT) scenario
Δ = Delta/difference; d = Discounted; ICER = Incremental Cost‑Effectiveness Ratio; Lys = Life Years; QALYs = Quality‑Adjusted Life Years
Figure 4. Cost-effectiveness of WCD in relation to WCD cost in the base-case (VEST ITT) scenario
ICER = Incremental Cost‑Effectiveness Ratio; QALY = Quality‑Adjusted Life Year; WCD = Wearable Cardioverter Defibrillator
Figure 5. Tornado Diagram (Post-MI C/E Model) – one way sensitivity analysis
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Results
COST EFFECTIVENESS OF WCD USED IN PATIENTS 
WITH ICD EXPLANT IN ITALY
We developed a decision‑analytic Markov model to estimate the lifetime costs of WCD 
versus standard of care in patients with implantable cardioverter defibrillator (ICD) re‑
moved due to infection.
Study Design
We decided to perform a cost‑minimization analysis instead of a cost‑effectiveness analy‑
sis assuming the same efficacy between the WCD and the standard of care in Italy (hospitaliza‑
tion in a low intensity hospital after ICD removal). The decision was based on a conservative 
approach considering that the only previous economic evaluation reported in the literature 
and conducted by Healy & Carrillo [37] used a WCD efficacy higher than hospitalization and 
clinical experts, involved in this HTA, suggested a higher efficacy for WCD.
The difference associated between the two compared interventions are related to the man‑
agement of time spent by patients without an ICD. In the time between the ICD explantation 
and the new ICD implantation (assumed 1 month based on clinical practice), patients can use 
a WCD and be discharged from the hospital waiting for the new implantation or be hospital‑
ized in a low intensity hospital until the new ICD implantation.
We discounted costs at an annual 3% rate [127,128] and performed the analysis from the 
perspective of the NHS. We expressed outcomes in terms of 2018 euro (€).
The data used to populate the model were obtained from the extensive literature research 
conducted from the present work (Table III).
Decision‑Analytic Model
We built a state‑transition Markov model 
to assess the overall costs associated to the 
use of WCD, using a lifetime time horizon 
and monthly cycle (Figure 7). A hypothetical 
cohort of patients with implantable cardio‑
verter defibrillators (ICD) removed due to in‑
fection, with a mean age of 61 years [37], 
can receive the WCD after the ICD removal 
or be hospitalized in a low intensity hospital. 
Patients stay in this health state for 1 month; 
after this time‑period, we assumed the reso‑
lution of infection and the implantation of a 
new ICD.
The new ICD implantation could be suc‑
cessful or result in procedural death. Patients 
Figure 6. Cost-effectiveness acceptability curve
with ICD entered in the post‑ICD health state where they could be hospitalized for heart fail‑
ure, experience new ICD infection, ICD generator replacement and die for cardiac death or 
other causes. We constructed the model by using Microsoft Excel.
Efficacy and Mortality
Based on the cost‑minimization analysis approach, we assumed the same efficacy between 
WCD and the standard of care (Table X). We modeled the efficacy of this intervention based 
on Sudden Cardiac Arrest (SCA) rates in the first month after ICD explantation and the WCD 
event survival of 85.5%, reported in the WCD registry. Event survival rate was defined as 
SCA rate due to VT/VF events as a part of all SCA events including e.g., asystoles, with a 
termination‑success of VT/VF events by the WCD of 100% [37,53]. This is a conservative ap‑
proach because “Hospitalization in a low intensity hospital” does not guarantee that patients 
are adequately protected from SCD unless they are on a monitored bed.
While for the long‑term mortality after the new ICD implantation, we modeled separately 
the non‑cardiac from the cardiac death following the approach used by Woo et al. [143]. 
Because the risk for death from general (non‑cardiac) causes increases with age, we sepa‑
rated the risk for death into general population and excess cardiac components. We based 
our general population mortality on the age specific risks for death from the Italian National 
Institute of Statistics [144]. In the patients who received an ICD, the excess of cardiac mor‑
tality (Table X) was estimated based on the overall mortality in the ICD group of SCD‑HeFT 
(Sudden Cardiac Death in Heart Failure) Trial [131] and on the prevalence of cardiac death 
in the MADIT‑II (Multicenter Automatic Defibrillator Implantation Trial) [132]. We held 
the excess cardiac mortality constant while allowing the general population mortality to rise 
with age; cardiac death therefore comprised a gradually decreasing fraction of the overall 
risk for death.
Further, we included a risk of death associated to ICD implantation and ICD lead failure 
in the model. [137,145]. We obtained the probabilities of lead failure from published registry 
data [134‑138,146]. Finally, based on these registry data, we also estimated the probability of 
ICD reinfection.
Costs
In the 30 days after ICD explanation, we included the cost of WCD and the cost of new 
ICD implantation for the WCD intervention and the cost of hospitalization in a low intensity 
hospital and the cost of a new ICD implantation for the standard of care (Table XI). In the 
analysis, we assumed a WCD cost of € 3,600 (based on Italian mean price provided by ZOLL) 
and a cost of € 5,250 for the hospitalization in a low intensive hospital (based on daily hospi‑
talization cost of € 250 and 21 days of hospitalization).
For the ICD implantation and the related interventions associated to ICD adverse events, 
we applied the cost associated to the appropriate Italian DRG (Table XI) [148]. The same ap‑
proach was used to estimate the cost associated to HF hospitalization in ICD patients.
Figure 7. Markov model for cost-minimization evaluation in ICD explant
ICD = Implantable Cardioverter Defibrillator; WCD = Wearable Cardioverter Defibrillator
Parameter Value References
Cohort mean age 61 Olgin 2018 [5]
Discount rate – cost 0.030 Sanders 2016 [127], Cortesi 2018 [128]
30 days after ICD explanation
Mortality WCD probability 0.0404 (0.0325‑0.0484) Chung 2010 [53], Healy 2015 [37]
Mortality Standard of Care 0.0404 (0.0325‑0.0484) Chung 2010 [53], Healy 2015 [37], assumption
ICD
Procedural death – monthly probability 0.0020 (0.0016‑0.0024) van Rees 2014 [130]
Cardiac mortality in patients with ICD – monthly 
probability
0.0044 (0.0035‑0.0052) Bardy 2005 [131]; Greenberg 2004 [132]
Probability of lead failure – monthly probability 0.0015 (0.0012‑0.0018) Kremers 2013 [133]
Probability of ICD infection – monthly probability 0.0007 (0.0006‑0.008) Kremers 2013 [133], Uslan 2007 [134], Margey 
2010 [135], Johansen 2011 [136]
Death from lead failure – monthly probability 0.0130 (0.0104‑0.0156) Cheng 2010 [137]
Battery life (replacement) 0.0113 (0.0091‑0.0136) Kramer 2013b [139]; Gandjour 2011 [140]
Hospitalization for HF 0.0080 (0.0064‑0.0096) Moss 2009 [141], Tang 2010 [142]
Table X. Clinical data input for cost-minimization model in ICD explant
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are adequately protected from SCD unless they are on a monitored bed.
While for the long‑term mortality after the new ICD implantation, we modeled separately 
the non‑cardiac from the cardiac death following the approach used by Woo et al. [143]. 
Because the risk for death from general (non‑cardiac) causes increases with age, we sepa‑
rated the risk for death into general population and excess cardiac components. We based 
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with age; cardiac death therefore comprised a gradually decreasing fraction of the overall 
risk for death.
Further, we included a risk of death associated to ICD implantation and ICD lead failure 
in the model. [137,145]. We obtained the probabilities of lead failure from published registry 
data [134‑138,146]. Finally, based on these registry data, we also estimated the probability of 
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ICD implantation for the WCD intervention and the cost of hospitalization in a low intensity 
hospital and the cost of a new ICD implantation for the standard of care (Table XI). In the 
analysis, we assumed a WCD cost of € 3,600 (based on Italian mean price provided by ZOLL) 
and a cost of € 5,250 for the hospitalization in a low intensive hospital (based on daily hospi‑
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Results
We estimated the expected battery lives of ICD devices according to previously reported 
data [139], assuming a mean battery life of 5 years and assuming no battery failure in the first 
2 years after ICD implantation [140]. For patients after ICD implantation, we associated the 
mean monthly costs after ICD reported by Smith et al. (Table X) [152].
Analysis
A base case analysis was performed based on the data input and assumptions described 
above, as sensing the cost of WCD and standard of care interventions, and the difference of 
overall costs associated to these interventions.
Further, we assessed the impact of WCD and hospitalization in a low‑intensive care hos‑
pital cost reducing and increasing their cost from ‑30% to +30%. To assess the reliability of 
results, we also performed a one‑way sensitivity analysis to test the impact of each parameter 
on the model results.
Results
In the base case scenario, the WCD result‑
ed as the less expensive treatment compared 
to Standard of care. Based on the cost‑mini‑
mization analysis, the WCD reported a cost 
reduction of € 1,782 per patient. (Table XII) 
Both the value of WCD and the Standard of 
care costs reported a high impact on the re‑
sults. In Figure 8 we observed a change in the 
Cost Value (€) References
Cost of WCD 3,600 (2,894‑4,306) Assumption
Cost of low intensity care 5,250 (4,221‑6,279) ASST rhodense, Expert opinion
Cost of ICD explanation due to non‑fatal infection 21,634 (17,394‑25,874 DRG 515 – G.U. 2013 [148]
30 days after ICD infection – WCD CD 25,234 (20,288‑30,180) Assumption, DRG 515 – G.U. 2013 [148]
30 days after ICD infection – Standard of care 26,884 (21,615‑32,153) ASST rhodense, Expert opinion, DRG 515 – 
G.U. 2013 [148]
Cost of ICD reimplantation after non‑fatal infection 0 ‑
Cost of ICD replacement 16,573 (13,258‑19,888) DRG 515 – G.U. 2013 [148]
Cost of revise due to lead problem 3,547 (2,837‑4,256) DRG 515 – G.U. 2013 [148]
Monthly cost after ICD implantation 345 (149‑541) Madotto 2015 [157]
HF hospitalization costs 4,898 (3,918‑5878) D'angiolella 2019 [151]
Table XI. Cost data inputs for cost-minimization model in ICD explant
cost saving from € 2,800 to € 810 assuming a WCD cost from €2,700 to €4,500. The same 
impact was found changing the Standard of care costs (Figure 9), with a cost saving associated 
to WCD ranging from € 3,500 to € 0 assuming a standard of care cost from € 6,800 to € 3,600.
WCD and standard of care costs resulted also as the parameters with a higher impact on 
the cost‑minimization results, based on the one‑way sensitive analysis (Figure 10).
Treatments Cost (€) Cost discounted (€)
WCD 105,175.35 86,035.52
Standard of care 106,997.92 87,817.92
∆ Cost (€) ∆ Cost discounted (€)
WCD vs Standard of care ‑1,822.58 ‑1,782.40
Table XII. Base-case (VEST ITT) scenario
Δ = delta/difference
Figure 8. Cost-minimization of WCD in relation to WCD cost
Figure 9. Cost-minimization of WCD in relation to Standard of care cost
Figure 10. Tornado Diagram (ICD Explant C/M Model) – one way sensitivity analysis
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Discussion 
and recommendation
In the European guidelines, published in 2015 [40], it is specified that “the WCD may 
be considered for adult patients with poor LV systolic function who are at risk of sudden 
arrhythmic death for a limited period, but are not candidates for an implantable defibrillator 
(e.g., bridge to transplant, bridge to transvenous implant, peripartum cardiomyopathy, active 
myocarditis and arrhythmias in the early post‑myocardial infarction phase).
More recently, the authors of the AHA/ACC/HRS Guideline for Management of Patients 
With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death [158] recommend 
the use of WCD in two categories of patients: those “with an ICD and a history of SCA or 
sustained VA in whom removal of the ICD is required (as with infection), in whom the WCD 
is reasonable for the prevention of SCD”; and “in patients at an increased risk of SCD but 
who are not eligible for an ICD, such as awaiting cardiac transplant, having an LVEF of 35% 
or less and are within 40 days from an MI, or have newly diagnosed NICM, revascularization 
within the past 90 days, myocarditis or secondary cardiomyopathy or a systemic infection, 
wearable cardioverter‑defibrillator may be reasonable”.
An HTA is a useful informative instrument to guide healthcare policymaking. It consists of 
a systematic evaluation of properties, effects, and/or impacts of a health care technology com‑
pared with its possible alternatives, for the management (diagnosis, prevention, treatment, 
care) of a specific condition. It may address the direct, intended consequences of technologies 
as well as their indirect, unintended consequences.
We conducted an HTA work on the use of WCD in two categories of subjects: adult pa‑
tients with a recent MI, and adult patients with an ICD explant.
Recently, Ettinger and colleagues [23,159] published an HTA on the use of the WCD 
to prevent SCA. However, there are some aspects that make this HTA work little useful to 
understand the value of WCD used in our healthcare system. Apart from a number of meth‑
odological drawbacks discussed between the authors of this work and Sperzel and colleagues 
[160,161], we specify below the aspects that are more significant to motivate the conduction 
of the present HTA work. First, the target patients considered and the criteria adopted to select 
the publications during the literature research were different than ours; second, no economic 
evaluation was conducted; Third, the approach of consulting a focus group is very interesting 
to collect information from the perspectives of interested individuals like patients, however, 
the authors involved only patients with no actual experience with the WCD, while it is recog‑
nized that having or not having an experience (i.e. using the WCD) can have significant im‑
plications on individuals’ opinions. The opinions reported only by subjects with no experience 
on the use of the WCD cannot be balanced, and would be better reported together or compared 
with the opinions of subjects with experience. Furthermore, they did not take the opportunity 
to involve clinicians as well, who would have contributed with their expert opinions in obtain‑
ing a more complete picture of implications of use of the WCD.
To perform the present HTA, we conducted a literature research, with the contribution of 
HTA and clinical experts. Further, due to the lack of specific economic evaluations conducted 
for the Italian setting, a cost‑effectiveness and a cost‑minimization analysis were conducted 
for the Post‑MI and ICD explant population, respectively. The main results are summarized 
and discussed below.
The main key messages from the most recent reviews [6,10,12,13,16,19,26,28,29] or me‑
ta‑analysis [9] in which studies involving subjects with previous MI or subjects with previous 
ICD explant were involved are specified below: the WCD effectively bridges a limited time 
period in patients with a high risk for SCA and may become a helpful tool for risk stratifi‑
cation to better select patients for primary prevention implantable cardioverter‑defibrillator 
placement. The WCD can be considered when a transient contraindication to ICD is present, 
such as endocarditis or device related infection. The WCD is recommended in several cases, 
including patients with an ICD and a history of SCA or sustained VA in whom removal of the 
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ICD is required, and patients at an increased risk of SCD but who are not eligible for an ICD, 
such as having an LVEF ≤ 35% and are within 40 days from an MI. The WCD is a feasible 
bridge to ICD therapy and/or safe observation for patients at high risk for SCD, especially 
in the acute recovery phase of cardiac diseases. Additionally, the WCD might provide a safe 
environment for long‑term observational studies even in patients at higher risk for SCD. The 
clinical value of the WCD must be measured not only by the number of terminated arrhythmic 
events, but also by successfully performed risk assessment and by the number of prevented 
non‑optimized guideline‑driven ICD implantations. Despite the fact that more recent studies 
have reported the clinical benefits in the target population, further research could be done to 
identify potential areas of improvement in terms of clinical outcome with the WCD. Data 
from long‑term experience with the WCD are needed to confirm these initial findings.
In regards to patients having experienced an MI, Barraud and colleagues [15] stated 
that the WCD was life‑saving in one patient after MI, although he used the device < 10 
hours a day. The small sample size limits the generalizability of the findings; however, the 
study confirms that the patient training is crucial to achieve good compliance. Kondo and 
colleagues [38] affirmed that early post‑MI patients at high risk of sudden cardiac death 
may benefit from WCD therapy, hence the WCD can contribute to prevent non‑optimized 
guideline‑driven ICD implantation. If persistent arrhythmia is detected, the WCD notifies 
the patient via a responsiveness test, allowing a conscious patient to prevent treatment. Most 
patients agreed that the device was easy to handle after sufficient training before receiving 
the device. Sanders et al. [41] reported that in patients with a recent MI and reduced LVEF, 
the use of a WCD could reduce the rate of SCD during the recovery period at a cost that ap‑
pears to be economically attractive. In 2013, Epstein and colleagues [49] stated that a select 
group of patients may benefit from defibrillation early after MI, particularly during the first 
30 days following hospital discharge (1.4% of patients were resuscitated by the WCD in the 
early weeks post‑MI). However, they suggested the conduction of further studies in the criti‑
cal period early post‑MI.
Castro and colleagues [20] reported that the WCD is a safe and efficient solution to protect 
patients from SCA while waiting for re‑implantation of a new ICD/CRT‑D device. The WCD 
reported a high efficacy for protecting patients from VT/VF and it can be used as an ICD alter‑
native in post‑ICD explanted patients. Healy and Carrillo [37] affirmed that the WCD is likely 
cost‑effective in protecting patients against SCA after infected ICD removal while waiting for 
ICD reimplantation compared to keeping patients in the hospital or discharging them home or 
to a skilled nursing facility. In 2014 Tanawuttiwat and colleagues [47] specified that in their 
study, compliance, which is essential for the effective use of the device, in general was rela‑
tively acceptable, and that WCD can prevent SCD, until ICD reimplantation is feasible in pa‑
tients who underwent device removals for ICD. In 2009, Wilkoff and colleagues [56] reported 
that when there is concern for ongoing infection, alternatives to early re‑implantation (after 
2‑3 days) include wearable defibrillators, epicardial lead implantation and surgical debride‑
ment of vegetations. However, at that time there was little published data and no consensus 
regarding the best approach for patients needing device re‑implantation.
Findings from the studies indicate that the WCD, though the cost of the device is usually 
high in most health systems, may be a cost‑effective option in appropriately selected patient 
groups. The cost‑effectiveness ratios appear to be acceptable. However, cost effectiveness is 
highly related to factors such as patient risk profile and device cost. The studies imply that to 
ensure cost‑effective use of WCD therapy, more and continuous research is needed. The cost 
of the device may be partly offset by reductions of hospitalizations and other resource use 
(costs due to device follow up, monitoring, complications, and replacement) and avoiding un‑
necessary ICD implant. However, generalizing the study results or trying to transfer them be‑
tween settings remain complex. The diversity in the methods used in such studies, differences 
in the patients involved, unit costs and resources utilized among different countries clearly 
affect the way in which costs and benefits of the treatments are accounted for and hence may 
also affect the conclusions.
In conclusion, despite the numerous advances, many gaps in knowledge about the costs 
and real‑world outcomes of WCD are recognized in the existing literature. These gaps in‑
clude:
 ‑ Identification of patients who are most likely to benefit from a WCD among all eligible 
patients;
 ‑ Characterizing the role of the WCD in patient subgroups not well‑represented in the trials;
 ‑ Evaluation of the impact of WCD use in clinical practice and introduction in treatment 
guidelines.
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Since patient selection is fundamental to high value care in using the WCD to prevent 
SCD, further evidence is needed to better define the appropriate patient group for the device 
and the target indication group [23,32]. Randomized trials for some of these indications with 
cost analyses would help the clinician in deciding the potential extended benefits of this de‑
vice and arguing the case with hospital and health fund administrators [32]. Although the 
cost‑effectiveness of WCD therapy is still to be confirmed, it is expected that the WCD will 
reduce the costs and improve the outcome in appropriately selected patients [30].
To conclude: SCA and SCD leads to serious health consequences for individuals and bur‑
den for the health care system [118‑121]. The experience on the use of WCD shows promising 
results, although some crucial points like costs, may interfere with the use of the WCD when 
clinically indicated. The overall benefits of the WCD, in terms of both safety and effective‑
ness, relate to patient acceptance and compliance. Acceptance and compliance can depend on 
communication between clinicians and patients and on appropriate training of patients. Com‑
munication and training require expertise and resources (human and financial). Investing on 
expertise and training could optimize compliance, hence effectiveness and safety. Information 
on compliance in Italy derives from the LifeVest Network database (registry maintained by 
manufacturer, ZOLL, Pittsburgh, PA), reporting 23.6 median hours of daily use, equivalent to 
those registered in Germany (median = 23.1 hours [36]) and in France (median = 23.4 [162]). 
Details on ethical/legal aspects and on organization implications of Life Vest are not deeply 
discussed in this HTA and further researche is needed to fully address these issues. However, 
the use of a wearable device generally reports few issues for the organization and ethical/legal 
aspects; indeed, WCD has the possibility to improve the organization and management of 
post‑MI and ICD explant patients with positive implication from the ethical point of view. For 
example, the use of WCD can avoid the hospitalization for ICD explant patients and the rela‑
tive organizational and management issues, providing more coverage (if used appropriately) 
from SCA and SCD.
In the post‑MI patients, the base‑case (VEST ITT) analysis performed with our cost‑ef‑
fectiveness model, reported an ICER of € 47,709 per QALY gained and of € 38,275 per LY 
gained comparing WCD vs medical therapy; an ICER that is below the highest cost‑effective‑
ness threshold of €60,000 per QALY gained reported in the economic‑evaluation conducted in 
Italy [153‑156]. This analysis was based on the overall mortality data estimated in the VEST 
trial by the Intention to Treat Analysis that reflects the low adherence to WCD of the patients 
involved in the trial [5]. Among 25 participants with adjudicated arrhythmic death, 9 were 
wearing the WCD at the time of death, 4 of whom received appropriate shocks and 5 of whom 
had no ventricular tachyarrhythmia. In order to assess the impact of wearing the WCD on sud‑
den death, non‑arrhythmic death, and total mortality, an “as treated” analysis was performed 
in the VEST trial to assess event rates per 100 person‑months of wearing the WCD compared 
to not wearing the WCD, and compared the two rates using Poisson regression. Based on 
this analysis, the VEST trial reported a total mortality rate of 0.50 per 100 person‑months 
of patients wearing the device, and 1.91 per 100 person‑months of patients not wearing the 
device reporting a higher efficacy of VEST (rate ratio, 0.26; 95% CI, 0.14 to 0.48; Bonferroni 
corrected p<0.001).
Although an economic model calculating WCD cost‑effectiveness was not conducted 
on the “As Treated” results; a “As Treated” Scenario Analysis is reasonable considering the 
higher adherence of WCD reported in the clinical practice. It is clear that cost calculations 
conducted with this data would be lower than those already reported for the ITT economic 
analysis.
However, the VEST trial, used as the main WCD efficacy data source in post‑MI patients, 
failed to provide a higher efficacy in reducing SCD compared to medical therapy. Many issues 
are associated to the solidity of these results based on the difficulty to classify SCD. Being 
aware that this issue requires further investigation to improve the assessment of WCD efficacy 
in post MI patients, we based the analysis on the overall mortality data following the opin‑
ions of clinical experts involved in this HTA. However, even considering the need of further 
studies with a better design to improve WCD adherence and cause of death identification, the 
cost‑effectiveness analysis provided in this HTA report could help decision makers to better 
understand the potential value of WCD in post MI patients.
The other Italian NHS specific economic evaluation on WCD reported in this HTA was 
a cost‑minimization analysis in patients with infected ICD explantation. In this analysis, the 
WCD provides a cost saving of € 1,782 per patient. These results were obtained assuming 
equal efficacy of WCD and Standard of care (3 weeks hospitalization in a low intensity hospi‑
tal), a conservative approach considering the only previous economic evaluation by Healy & 
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Carrillo [37] where WCD efficacy was considered higher than hospitalization. However, even 
with this conservative approach, the WCD resulted as the less expensive treatment option 
with cost savings for the NHS budget. These results were confirmed in the sensitivity analysis.
The cost‑effectiveness acceptability curve (CEAC) seen in Figure 6 shows the probability 
that the WCD is cost‑effective compared with standard medical management, for a range of 
monetary values that a decision‑maker might consider the maximum acceptable to avoid sud‑
den cardiac arrest or death. This range of maximum monetary values, expressed as Euros per 
the probability of being cost‑effective, is given on the x‑axis. Given a specified value of this 
‘acceptable’ cost‑effectiveness ratio (a point on the x‑axis), the CEAC shows the probability 
that the data are consistent with a true cost‑effectiveness ratio falling below a willingness to 
pay value (read off the y‑axis).
In the case of the WCD, given a maximum acceptable ratio of € 60,000, the probability 
that the WCD therapy is cost‑effective compared with routine medical treatment is 0.55. This 
is equivalent to stating that, given the data, there is a 55% chance that the additional cost of 
WCD therapy, compared with routine medical management, is less than the willingness to 
pay threshold of €60,000 per QALY gained reported in the economic‑evaluation conducted in 
Italy [153‑156]. Note the comparative nature of both statements. It is not equivalent to stating 
that the WCD therapy has a 55% chance of costing less than € 60,000.
The use of WCD in post‑MI patients or with an ICD explant and demographic and clini‑
cal characteristics that are typically observed and similar to those used in the two economic 
models applied in the present HTA, was found to be cost‑effective in the first and cost‑saving 
in the second group of patients. The two present some limitations, deriving from the use of 
data from different literature sources to make assumptions for the construction of the two 
models, which would deserve to be confirmed by more robust data obtained from a real‑world 
application experience for a long‑time horizon in the different regional health services of Italy.
In conclusion, the use of WCD according to guidelines can therefore contribute not only 
to an improvement in patient care in clinical practice, but also to a more effective utilization 
of resources in the Italian NHS. In addition, further research on risk factors for SCA and SCD 
should be conducted to continue to improve the identification of the target population. All 
evidence provided in this HTA was considered reliable by Italian clinical and HTA experts. 
Accordingly, the results can be considered applicable within the Italian NHS.
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